var title_f7_10_7328="Slit lamp ocular lens";
var content_f7_10_7328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp ocular lens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Set each ocular lens to \"0\" as shown here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7328=[""].join("\n");
var outline_f7_10_7328=null;
var title_f7_10_7329="Bencyclane: International drug information";
var content_f7_10_7329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bencyclane: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fludilat (BR, DE, PT, TH);",
"     </li>",
"     <li>",
"      Halidor (HU, RU);",
"     </li>",
"     <li>",
"      Ludilat (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F3466504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Benzacyclane Fumarate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3466505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of peripheral and cerebral vascular disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Adults: 100-200 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10479 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-0E46A87C69-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7329=[""].join("\n");
var outline_f7_10_7329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302635\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466504\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466505\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466506\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466508\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821218\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466509\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7330="Suprapubic aspiration technique";
var content_f7_10_7330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Needle insertion technique for suprapubic aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is inserted one to two centimeters above the pubic symphysis and angled 10 to 20 degrees cephalad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7330=[""].join("\n");
var outline_f7_10_7330=null;
var title_f7_10_7331="Fetal ascites transverse view";
var content_f7_10_7331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse view of fetal abdomen showing anechoic rim of abdominal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Svena Julien, MD and Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7331=[""].join("\n");
var outline_f7_10_7331=null;
var title_f7_10_7332="Pseudoephedrine and dextromethorphan: Drug information";
var content_f7_10_7332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/25/5525?source=see_link\">",
"    see \"Pseudoephedrine and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pedia Relief Cough and Cold [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Children's Cold &amp; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM D;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-D;",
"     </li>",
"     <li>",
"      Koffex DM-D;",
"     </li>",
"     <li>",
"      Novahistex&reg; DM Decongestant;",
"     </li>",
"     <li>",
"      Novahistine&reg; DM Decongestant;",
"     </li>",
"     <li>",
"      Robitussin&reg; Childrens Cough &amp; Cold",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive/Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of nasal congestion and cough:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     General dosing guidelines base on pseudoephedrine component: Oral: 60 mg every 4-6 hours (maximum: 240 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Product-specific dosing: Oral: Sudafed&reg; Children's Cold &amp; Cough: 20 mL every 4 hours (maximum: 80 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of nasal congestion and cough:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     General dosing guidelines base on pseudoephedrine component: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years: 15 mg every 4-6 hours (maximum: 60 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 30 mg every 4-6 hours (maximum: 120 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 60 mg every 4-6 hours (maximum: 240 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Product-specific dosing: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years (Sudafed&reg; Children's Cold &amp; Cough): 5 mL every 4 hours (maximum: 20 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years (Sudafed&reg; Children's Cold &amp; Cough): 10 mL every 4 hours (maximum: 40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; Children's Cold &amp; Cough: Pseudoephedrine hydrochloride 15 mg and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL) [alcohol free, sugar free; contains sodium benzoate; cherry berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pedia Relief Cough and Cold: Pseudoephedrine hydrochloride 15 mg and dextromethorphan hydrobromide 7.5 mg per 5 mL (120 mL) [cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Syrup",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary symptomatic relief of nasal congestion and cough due to common cold, hay fever, upper respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine, dextromethorphan, or any component of the formulation; use with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (hypertension or ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F215405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F215393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM D (CA);",
"     </li>",
"     <li>",
"      Benylin DM-D (CA);",
"     </li>",
"     <li>",
"      Koffex DM-D (CA);",
"     </li>",
"     <li>",
"      Novahistex DM Decongestant (CA);",
"     </li>",
"     <li>",
"      Novahistine DM Decongestant (CA);",
"     </li>",
"     <li>",
"      Robitussin Childrens Cough &amp; Cold (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10235 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-87592D432B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7332=[""].join("\n");
var outline_f7_10_7332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215395\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215396\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215408\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215399\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215404\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215400\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215386\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215377\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215388\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215406\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215391\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215380\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215405\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215384\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215393\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215390\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/25/5525?source=related_link\">",
"      Pseudoephedrine and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7333="Natalizumab: Patient drug information";
var content_f7_10_7333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Natalizumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     see \"Natalizumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tysabri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5594359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tysabri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause a very bad brain infection called PML (progressive multifocal leukoencephalopathy). People with a weak immune systems have more chance of getting this infection. Read the part in this leaflet which tells you when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only U.S. patients in the TOUCH Prescribing Program may get this drug. Canadian patients need to enroll in the Canadian Tysabri Care Program&trade; at 1-888-827-2827.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Crohn's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702576",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to natalizumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to mouse proteins, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a brain infection called progressive multifocal leukoencephalopathy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11990 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7333=[""].join("\n");
var outline_f7_10_7333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5594359\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021011\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021013\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021012\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021017\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021018\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021020\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021015\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021016\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021022\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=related_link\">",
"      Natalizumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7334="Ethacrynic acid: Drug information";
var content_f7_10_7334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethacrynic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/36/40517?source=see_link\">",
"    see \"Ethacrynic acid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/11/29877?source=see_link\">",
"    see \"Ethacrynic acid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Edecrin&reg;;",
"     </li>",
"     <li>",
"      Sodium Edecrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Edecrin&reg;;",
"     </li>",
"     <li>",
"      Sodium Edecrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Loop",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. formulation should be diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS (1 mg/mL) and infused over several minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Edema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-200 mg/day in 1-2 divided doses; may increase in increments of 25-50 mg at intervals of several days to a maximum of 400 mg/24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.5-1 mg/kg/dose (maximum: 100 mg/dose); repeat doses not routinely recommended; however, if indicated, repeat doses every 8-12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F167984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/11/29877?source=see_link\">",
"      see \"Ethacrynic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Edema: Oral: Children: 1 mg/kg/dose once daily; increase at intervals of 2-3 days as needed, to a maximum of 3 mg/kg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 25-50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F167969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling, use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as ethacrynate sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sodium Edecrin&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edecrin&reg;: 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F167943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection should",
"     <b>",
"      not",
"     </b>",
"     be given SubQ or I.M. due to local pain and irritation; single I.V. doses should not exceed 100 mg; if a second dose is needed, use a new injection site to avoid possible thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F168002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with whole blood or its derivatives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, heparin with hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Nesiritide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with congestive heart failure; hepatic cirrhosis or renal disease; short-term management of ascites due to malignancy, idiopathic edema, and lymphedema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Edecrin&reg; may be confused with Eulexin, Ecotrin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, fatigue, apprehension, confusion, fever, chills, encephalopathy (patients with pre-existing liver disease); vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, Henoch-Sch&ouml;nlein purpura (in patient with rheumatic heart disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia, hyperglycemia, variations in phosphorus, CO",
"     <sub>",
"      2",
"     </sub>",
"     content, bicarbonate, and calcium; reversible hyperuricemia, gout, hyperglycemia, hypoglycemia (occurred in two uremic patients who received doses above those recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, malaise, abdominal discomfort or pain, dysphagia, nausea, vomiting, and diarrhea, gastrointestinal bleeding, acute pancreatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice, abnormal liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematology: Agranulocytosis, severe neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis (with intravenous use), local irritation and pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus, temporary or permanent deafness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Increased serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethacrynic acid or any component of the formulation; anuria; history of severe watery diarrhea caused by this product; infants",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Loop diuretics are potent diuretics; excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Can rarely occur, however, ethacrynic acid has no cross-reactivity to  sulfonamides or sulfonylureas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity: Rapid I.V. administration, renal impairment, excessive doses, and concurrent use of other ototoxins is associated with ototoxicity; has been associated with a higher incidence of ototoxicity than other loop diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Coadministration of antihypertensives may increase the risk of hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Loop Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: May enhance the ototoxic effect of Ethacrynic Acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Loop Diuretics may diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ethacrynic Acid may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available. Generally, use of diuretics during pregnancy is avoided due to risk of decreased placental perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product may cause a potassium loss. Your healthcare provider may prescribe a potassium supplement, another medication to help prevent the potassium loss, or recommend that you eat foods high in potassium, especially citrus fruits. Do not change your diet on your own while taking this medication, especially if you are taking potassium supplements or medications to reduce potassium loss. Too much potassium can be as harmful as too little.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Sodium Edecrin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $1068.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Edecrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $552.23",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, renal function, serum electrolytes, and fluid status closely, including weight and I &amp; O daily; hearing",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Edecril (NL);",
"     </li>",
"     <li>",
"      Edecrin (AT, AU, CZ, GB, IE, NL);",
"     </li>",
"     <li>",
"      Edecrina (SE);",
"     </li>",
"     <li>",
"      Hydromedin (DE);",
"     </li>",
"     <li>",
"      Hydromedin i.v.[inj.] (DE);",
"     </li>",
"     <li>",
"      Reomax (IT);",
"     </li>",
"     <li>",
"      Uregyt (CZ, DE, HN, HU, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: Oral: ~30 minutes; I.V.: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: 2 hours; I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 12 hours; I.V.: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (35% to 40%) to active cysteine conjugate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces and urine (30% to 60% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cowley AJ and Elkeles RS, &ldquo;Diabetes and Therapy With Potent Diuretics,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1978, 1(8056):154.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Felker GM, Lee KL, Bull DA, et al, \"Diuretic Strategies in Patients With Acute Decompensated Heart Failure,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(9):797-805.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/10/7334/abstract-text/21366472/pubmed\" id=\"21366472\" target=\"_blank\">",
"        21366472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gomolin IH and Garschick E, &ldquo;Ethacrynic Acid-Induced Deafness Accompanied by Nystagmus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1980, 303(12):702.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lant A, &ldquo;Diuretics: Clinical Pharmacology and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1985, 29(1):57-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/10/7334/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9429 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7334=[""].join("\n");
var outline_f7_10_7334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167963\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167964\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167995\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167967\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167984\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167968\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167969\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881369\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167939\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167924\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167943\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168002\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167942\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168004\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167993\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167947\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167928\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299289\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167933\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167934\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167950\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167973\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167951\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167949\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167937\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038612\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167927\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167946\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9429|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/36/40517?source=related_link\">",
"      Ethacrynic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/11/29877?source=related_link\">",
"      Ethacrynic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7335="Lymphocytic interstitial pneumonitis in children";
var content_f7_10_7335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lymphocytic interstitial pneumonitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Cynthia E Epstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Leland L Fan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7335/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7335/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/10/7335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic interstitial pneumonitis (LIP) remains in the differential diagnosis for interstitial lung disease (ILD) in childhood, although it is actually a form of pulmonary lymphoproliferative disease. Other benign lymphoid disorders of the lung include intraparenchymal lymph nodes, bronchial associated lymphoid hyperplasia, nodular lymphoid hyperplasia, and angioimmunoblastic lymphadenopathy. It is important to distinguish LIP from these other disorders histologically because they have different treatment regimens and prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of LIP in infants and children will be presented here. LIP in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=see_link\">",
"     \"Lymphoid interstitial pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIP is the most common form of classically described pediatric ILD. LIP most often occurs in association with underlying conditions, such as autoimmune disease and immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], but also occurs in familial and idiopathic forms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. LIP occurs in 25 to 40 percent of children with perinatally acquired HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/8\">",
"     8",
"    </a>",
"    ], and usually presents in the second or third year of life. LIP is an AIDS-defining condition in HIV-infected children, but not in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840519#H18840519\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Lymphoid interstitial pneumonia/pulmonary lymphoid hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIP is characterized by a diffuse infiltrate of mature and immature lymphocytes, plasma cells, and histiocytes in the alveolar septae and pulmonary interstitium (",
"    <a class=\"graphic graphic_picture graphicRef71770 \" href=\"UTD.htm?0/55/886\">",
"     picture 1",
"    </a>",
"    ). Nodular formation of lymphocytes is commonly seen, occasionally with germinal centers. The cellular infiltrate is polyclonal, including both B and T cells, usually with a predominance of CD8 lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/9\">",
"     9",
"    </a>",
"    ]. The blood vessels and airways are not involved in this process and fibrosis is not a typical feature. However, if there is a significant nodular component, it may distort the pulmonary architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis of LIP is unknown, several theories have been suggested. LIP may result from an exaggerated immunologic response to inhaled or circulating antigens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    caused by a primary infection with Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], HIV, or an unknown source [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/3\">",
"     3",
"    </a>",
"    ]. Immune dysregulation may play a role in the pathogenesis of LIP, and in some cases, LIP may be a premalignant state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/12\">",
"     12",
"    </a>",
"    ]. An immunogenetic basis also has been postulated since HLA-DR5 markers have been found in adults with LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/13\">",
"     13",
"    </a>",
"    ]. There is an active investigation into the role of cytokines in the pathogenesis of LIP. TNF-alpha and IL-1 are elevated to a greater extent in children with HIV and LIP than in children with HIV without LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of EBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous investigations, limited by the small number of included patients, have shown evidence of EBV in patients with HIV infection and LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/10,11,15,16\">",
"     10,11,15,16",
"    </a>",
"    ]. However, the role of EBV infection in the development of LIP remains unclear. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study examining lung biopsy specimens from 17 patients with AIDS, EBV DNA was detected in 8 of the 10 biopsy specimens diagnosed with LIP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-control study of HIV infected children, serologic evidence of recrudescent or primary EBV infection was observed in all seven children with LIP but in only 2 of 13 children (15 percent) without LIP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of nine children vertically infected with HIV-1 Subtype E who had biopsy-proven LIP, all had EBV identified in the lung by EBV-encoded RNA in situ hybridization. Interestingly, in six of nine cases, EBV was found in 30 to 50 percent of Langerhans and related dendritic cells, whereas only 30 percent of T and B cells were infected, suggesting that Langerhans cells are more readily infected and may be a reservoir for EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 20 children with HIV-1 and chronic lung disease, EBV expression was detected in the majority of lung samples but without significant association with pulmonary lymphoid",
"      <span class=\"nowrap\">",
"       hyperplasia/lymphocytic",
"      </span>",
"      interstitial pneumonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of EBV infection in non-HIV-related LIP also is unclear. EBV associated LIP has been reported in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/19\">",
"     19",
"    </a>",
"    ] and children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] without HIV infection. In one study of seven lung biopsy specimens from patients with LIP, EBV DNA was detected in three specimens by polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/19\">",
"     19",
"    </a>",
"    ]. This suggests that EBV may be associated with some, but not all cases of non-HIV-related LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are many similarities, it is important to distinguish HIV-related from non-HIV related LIP since the treatment varies. In addition, lung biopsy, which is required for diagnosis of non-HIV related LIP, may not be necessary in children with HIV. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HIV-related LIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIP is more common in perinatally-acquired than in transfusion-acquired HIV. Before intervention to prevent perinatal transmission of HIV infection became widely available in the United States, children with perinatally acquired HIV infection typically presented in the second to third year of life. In one retrospective review of 172 children with perinatally acquired HIV, 17 percent presented with LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/22\">",
"     22",
"    </a>",
"    ]. The median age of presentation with LIP was 14 months, with a range of 5 to 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of HIV-related LIP generally is insidious. Cough and tachypnea are often noted. However, auscultation of the chest reveals few abnormalities. Digital clubbing occurs commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/23\">",
"     23",
"    </a>",
"    ]. Extrapulmonary manifestations include generalized lymphadenopathy, hepatosplenomegaly, and salivary gland enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/24\">",
"     24",
"    </a>",
"    ]. Hypergammaglobulinemia, which is usually present, is thought to be secondary to an imbalance of immunoregulatory cells in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course is variable. Spontaneous clinical remission sometimes is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/25\">",
"     25",
"    </a>",
"    ]. Exacerbation of clinical signs and symptoms may occur in association with intercurrent viral respiratory illnesses. In severe cases, progressive hypoxia and respiratory failure occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Non-HIV-related LIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HIV related LIP is less common than HIV-related LIP. Non-HIV-related LIP shares the classic presentation of other forms of ILD, including symptoms of tachypnea, cough, dyspnea, exercise intolerance, and frequent respiratory infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .) In the absence of HIV, other causes of immunodeficiency and autoimmune disorders should be considered.",
"   </p>",
"   <p>",
"    On physical examination, the most common findings include retractions, tachypnea, and basilar crackles. Evidence of growth failure, cyanosis, clubbing, and increased intensity of the second component of the second heart sound (P2) are present in the more severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/26\">",
"     26",
"    </a>",
"    ]. Generalized lymphadenopathy is rare; if it is detected, malignancy should be considered. Hypogammaglobulinemia is present occasionally [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung biopsy is usually necessary to diagnose LIP and to distinguish it from benign lymphoid disorders of the lung. However, in patients with documented HIV infection, the presentation of dyspnea with associated hypoxia and classic radiographic findings of micronodular infiltrates may be enough for the diagnosis of LIP without further invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing in both HIV-related and non-HIV-related LIP, as in other forms of ILD, typically demonstrates a pattern of restrictive disease, with reduced forced vital capacity (FVC) and forced vital capacity in one second (FEV1) as well as normal",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/1\">",
"     1",
"    </a>",
"    ]. Measurement of oxygen saturation with pulse oximetry helps to determine the severity of illness and may have prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the infant and child with interstitial lung disease\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography in HIV-related LIP typically reveals a diffuse symmetric reticulonodular or nodular pattern occasionally associated with mediastinal or hilar adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/27\">",
"     27",
"    </a>",
"    ]. The nodular pattern can wax and wane, and has been noted to disappear completely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/29\">",
"     29",
"    </a>",
"    ]. In some cases, hyperinflation may be the only radiographic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/30\">",
"     30",
"    </a>",
"    ]. Air space consolidation, bronchiectasis, and cystic lung changes have been observed in advanced disease.",
"   </p>",
"   <p>",
"    As in HIV-related LIP, the radiographic pattern of non-HIV-related LIP is typically a diffuse reticulonodular pattern most prominent in the lower lobes, but may vary from a purely linear interstitial process affecting the bases and perihilar regions to a more nodular process [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/31\">",
"     31",
"    </a>",
"    ]. However, a ground glass abnormality may be the only radiographic finding (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82288 \" href=\"UTD.htm?31/14/31973\">",
"     image 1",
"    </a>",
"    ). Mediastinal or hilar adenopathy is rarely found, and if detected, should warrant further investigation for a malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-resolution computerized tomography (HRCT) scans provide important details about the extent and distribution of the parenchymal disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82288 \" href=\"UTD.htm?31/14/31973\">",
"     image 1",
"    </a>",
"    ), combining thin-section computed tomography (CT) with a high frequency resolution algorithm to reduce the field of view to image one lung or a portion of one lung. With this enhanced detail, favorable biopsy sites can be selected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung biopsy remains the gold standard for the diagnosis of non-HIV-related LIP and is important in confirming the diagnosis of HIV-related LIP, particularly in cases with an unusual presentation. Transbronchial biopsy is used primarily to diagnose infections or rejection in patients after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/33\">",
"     33",
"    </a>",
"    ], but has limited use in the primary diagnosis of LIP.",
"   </p>",
"   <p>",
"    Transthoracic lung biopsy, either with open lung biopsy (OLB) or video assisted thoracoscopy (VATS), is the preferred method to obtain lung tissue for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/34\">",
"     34",
"    </a>",
"    ]. The diagnostic yield of VATS and OLB are similar. However, because VATS has less morbidity with respect to duration of surgery, chest tube drainage, and hospitalization, it is becoming the method of choice for lung biopsy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/35\">",
"     35",
"    </a>",
"    ]. Whatever method is used, the lung biopsy specimen must be processed in a consistent manner, and should be analyzed by an experienced pediatric pathologist. The characteristic pathologic findings are described above (",
"    <a class=\"graphic graphic_picture graphicRef71770 \" href=\"UTD.htm?0/55/886\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for patients with pediatric LIP involves both supportive care and pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive therapy for children with LIP is the same as it is for children with other forms of ILD and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the infant and child with interstitial lung disease\", section on 'Supportive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic therapy for pediatric LIP differs for HIV-related and non-HIV-related illness. For those with LIP and HIV infection, use of antiviral agents to control the underlying HIV infection is critical. In addition, periodic intravenous gammaglobulin has shown to be useful for slowing and even halting progression of LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For both HIV-related and non-HIV-related LIP, corticosteroid therapy has been shown to be beneficial in uncontrolled studies, with improved respiratory symptoms and decreased oxygen requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/36\">",
"     36",
"    </a>",
"    ]. Pulse therapy with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [maximum 1000 mg], administered over one hour, for three consecutive days each month) is an alternative to daily therapy and may be equally or more effective with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Children with HIV-related LIP should receive prophylaxis for Pneumocystis carinii pneumonia (PCP, now renamed Pneumocystis jirovecii pneumonia) if they are receiving systemic corticosteroid treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is an alternative to corticosteroid therapy. In anecdotal reports, it has been effective in HIV-related LIP and in LIP related to other immune deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The recommended dose in children is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. In severely immunocompromised patients, hydroxychloroquine may be preferred to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for children with LIP is variable, although the overall long-term mortality rate is high. Spontaneous resolution has been noted, but more commonly episodic worsening leading to progression of frank respiratory failure is seen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LIP is a CDC class B disease in HIV infected patients, indicative of a better prognosis than other AIDS-defining illnesses. However, there is evidence of considerable chronic respiratory morbidity associated with LIP and HIV. The incidence of acute lower respiratory tract infection in children with LIP is twice the rate of those infected with HIV without LIP, and tenfold higher than reported in non-HIV infected children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840519#H18840519\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Lymphoid interstitial pneumonia/pulmonary lymphoid hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, LIP infection can lead to bronchiectasis and cystic changes within the lung resulting in chronic respiratory infections and even respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/42\">",
"     42",
"    </a>",
"    ]. Death in both HIV-related and non-HIV-related LIP may occur secondary to infectious complications of treatment, end-stage pulmonary fibrosis, or rarely, malignant lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7335/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18163162\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphocytic interstitial pneumonitis (LIP) remains a form of pulmonary lymphoproliferative disease. LIP most often occurs in association with underlying conditions, such as autoimmune disease and immunodeficiencies, but also occurs in familial and idiopathic forms. LIP occurs in 25 to 40 percent of children with perinatally acquired HIV and usually presents in the second or third year of life. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LIP may result from an exaggerated immunologic response to inhaled or circulating antigens",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      caused by a primary infection with Epstein-Barr virus (EBV), HIV, or an unknown source. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with perinatally acquired HIV infection, LIP typically presents in the second or third year of life. The onset of HIV-related LIP generally is insidious, with cough and tachypnea and sometimes digital clubbing and hypergammaglobulinemia. The clinical course is variable, and spontaneous clinical remission sometimes is observed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HIV-related LIP'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Non-HIV related LIP is less common than HIV-related LIP. Non-HIV-related LIP shares the classic presentation of other forms of ILD, including symptoms of tachypnea, cough, dyspnea, exercise intolerance, and frequent respiratory infections. In the absence of HIV, other causes of immunodeficiency and autoimmune disorders should be considered. Generalized lymphadenopathy is rare; if it is detected, malignancy should be considered. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Non-HIV-related LIP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiography in LIP typically reveals a diffuse symmetric reticulonodular or nodular pattern occasionally associated with mediastinal or hilar adenopathy. Lung biopsy remains the gold standard for the diagnosis of non-HIV-related LIP and is important in confirming the diagnosis of HIV-related LIP. In patients with documented HIV infection, the presence of typical clinical and radiographic features may be sufficient to make the diagnosis without lung biopsy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pharmacologic therapy for pediatric LIP differs for HIV-related and non-HIV-related illness. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For both HIV-related and non-HIV-related LIP, corticosteroid therapy has been shown to be beneficial in uncontrolled studies.",
"     </li>",
"     <li>",
"      For children with HIV-related LIP, use of antiviral agents to control the underlying HIV infection is critical. In addition, periodic intravenous gammaglobulin has shown to be useful for slowing and even halting progression of LIP.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      is an alternative to corticosteroid therapy. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fan LL. Pediatric interstitial lung disease. In: Interstitial Lung Disease, Schwarz MI, King TE (Eds), BC Decker, Hamilton 2003. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/2\">",
"      Lovell D, Lindsley C, Langston C. Lymphoid interstitial pneumonia in juvenile rheumatoid arthritis. J Pediatr 1984; 105:947.",
"     </a>",
"    </li>",
"    <li>",
"     Hepburn B. Interstitial lung disease in childhood rheumatic disorders. In: Interstitial Lung Disease in Children, Laraya-Cuasay LR, Hughes WT (Eds), CRC Press, Boca Raton 1988. Vol 3, p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/4\">",
"      Joshi VV, Oleske JM, Minnefor AB, et al. Pathologic pulmonary findings in children with the acquired immunodeficiency syndrome: a study of ten cases. Hum Pathol 1985; 16:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/5\">",
"      Church JA, Isaacs H, Saxon A, et al. Lymphoid interstitial pneumonitis and hypogammaglobulinemia in children. Am Rev Respir Dis 1981; 124:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/6\">",
"      Rogers BB, Browning I, Rosenblatt H, et al. A familial lymphoproliferative disorder presenting with primary pulmonary manifestations. Am Rev Respir Dis 1992; 145:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/7\">",
"      Franchi LM, Chin TW, Nussbaum E, et al. Familial pulmonary nodular lymphoid hyperplasia. J Pediatr 1992; 121:89.",
"     </a>",
"    </li>",
"    <li>",
"     Andiman WA, Shearer WT. Lymphoid interstitial pneumonitis. In: Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, 3rd, Pizzo PA, Wilfert CM (Eds), Lippincott Williams &amp; Wilkins, Baltimore 1998. p.323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/9\">",
"      Koss MN. Pulmonary lymphoid disorders. Semin Diagn Pathol 1995; 12:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/10\">",
"      Andiman WA, Eastman R, Martin K, et al. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet 1985; 2:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/11\">",
"      Montagnier L, Gruest J, Chamaret S, et al. Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science 1984; 225:63.",
"     </a>",
"    </li>",
"    <li>",
"     Laraya-Cuasay LR. Lymphoproliferative disorders of the lung. In: Interstitial Lung Disease in Children, Laraya-Cuasay LR, Hughes WT (Eds), CRC Press, Boca Raton 1988. Vol 3, p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/13\">",
"      Pitt J. Lymphocytic interstitial pneumonia. Pediatr Clin North Am 1991; 38:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/14\">",
"      Arditi M, Kabat W, Yogev R. Serum tumor necrosis factor alpha, interleukin 1-beta, p24 antigen concentrations and CD4+ cells at various stages of human immunodeficiency virus 1 infection in children. Pediatr Infect Dis J 1991; 10:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/15\">",
"      Joshi VV, Kauffman S, Oleske JM, et al. Polyclonal polymorphic B-cell lymphoproliferative disorder with prominent pulmonary involvement in children with acquired immune deficiency syndrome. Cancer 1987; 59:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/16\">",
"      Katz BZ, Berkman AB, Shapiro ED. Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. J Pediatr 1992; 120:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/17\">",
"      Bhoopat L, Rangkakulnuwat S, Okonogi R, et al. Cell reservoirs of the Epstein-Barr virus in biopsy-proven lymphocytic interstitial pneumonitis in HIV-1 subtype E infected children: identification by combined in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 2010; 18:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/18\">",
"      Toro AA, Altemani AM, da Silva MT, et al. Epstein-Barr virus (EBV) gene expression in interstitial pneumonitis in Brazilian human immunodeficiency virus-1-infected children: is EBV associated or not? Pediatr Dev Pathol 2010; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/19\">",
"      Malamou-Mitsi V, Tsai MM, Gal AA, et al. Lymphoid interstitial pneumonia not associated with HIV infection: role of Epstein-Barr virus. Mod Pathol 1992; 5:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/20\">",
"      Mueller GA, Pickoff AS. Pediatric lymphocytic interstitial pneumonitis in an HIV-negative child with pulmonary Epstein-Barr virus infection. Pediatr Pulmonol 2003; 36:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/21\">",
"      Pfleger A, Eber E, Popper H, Zach MS. Chronic interstitial lung disease due to Epstein-Barr virus infection in two infants. Eur Respir J 2000; 15:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/22\">",
"      Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989; 321:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/23\">",
"      Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol 2008; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/24\">",
"      Katkin JP, Hansen TN, Langston C, et al. Pulmonary manifestations of AIDS in children. Semin Pediatr Infect Dis 1990; 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/25\">",
"      Rubinstein A, Morecki R, Goldman H. Pulmonary disease in infants and children. Clin Chest Med 1988; 9:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/26\">",
"      Fan LL, Mullen AL, Brugman SM, et al. Clinical spectrum of chronic interstitial lung disease in children. J Pediatr 1992; 121:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/27\">",
"      Marks MJ, Haney PJ, McDermott MP, et al. Thoracic disease in children with AIDS. Radiographics 1996; 16:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/28\">",
"      Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med 1997; 156:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/29\">",
"      Marquis JR, Berman CZ, DiCarlo F, Oleske JM. Radiographic patterns of PLH/LIP in HIV positive children. Pediatr Radiol 1993; 23:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/30\">",
"      Schneider RF. Lymphocytic interstitial pneumonitis and nonspecific interstitial pneumonitis. Clin Chest Med 1996; 17:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/31\">",
"      Bragg DG, Chor PJ, Murray KA, Kjeldsberg CR. Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features. AJR Am J Roentgenol 1994; 163:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/32\">",
"      Lynch DA, Hay T, Newell JD Jr, et al. Pediatric diffuse lung disease: diagnosis and classification using high-resolution CT. AJR Am J Roentgenol 1999; 173:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/33\">",
"      Kurland G, Noyes BE, Jaffe R, et al. Bronchoalveolar lavage and transbronchial biopsy in children following heart-lung and lung transplantation. Chest 1993; 104:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/34\">",
"      Rothenberg SS, Wagner JS, Chang JH, Fan LL. The safety and efficacy of thoracoscopic lung biopsy for diagnosis and treatment in infants and children. J Pediatr Surg 1996; 31:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/35\">",
"      Fan LL, Kozinetz CA, Wojtczak HA, et al. Diagnostic value of transbronchial, thoracoscopic, and open lung biopsy in immunocompetent children with chronic interstitial lung disease. J Pediatr 1997; 131:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/36\">",
"      Rubinstein A, Bernstein LJ, Charytan M, et al. Corticosteroid treatment for pulmonary lymphoid hyperplasia in children with the acquired immune deficiency syndrome. Pediatr Pulmonol 1988; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/37\">",
"      Desmarquest P, Tamalet A, Fauroux B, et al. Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses. Pediatr Pulmonol 1998; 26:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/38\">",
"      Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/39\">",
"      Waters KA, Bale P, Isaacs D, Mellis C. Successful chloroquine therapy in a child with lymphoid interstitial pneumonitis. J Pediatr 1991; 119:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/40\">",
"      Campos JM, Simonetti JP. Treatment of lymphoid interstitial pneumonia with chloroquine. J Pediatr 1993; 122:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/41\">",
"      Sharland M, Gibb DM, Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997; 76:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7335/abstract/42\">",
"      Sheikh S, Madiraju K, Steiner P, Rao M. Bronchiectasis in pediatric AIDS. Chest 1997; 112:1202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6348 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7335=[""].join("\n");
var outline_f7_10_7335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18163162\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of EBV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV-related LIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Non-HIV-related LIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18163162\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6348|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/14/31973\" title=\"diagnostic image 1\">",
"      LIP CXR and HRCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6348|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/55/886\" title=\"picture 1\">",
"      LIP lung biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=related_link\">",
"      Lymphoid interstitial pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7336="Endometrial polyps";
var content_f7_10_7336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometrial polyps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Elizabeth A Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7336/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/10/7336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps are one of the most common etiologies of abnormal genital bleeding in both premenopausal and postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. They are hyperplastic overgrowths of endometrial glands and stroma that form a projection from the surface of the endometrium (lining of the uterus). They may also be asymptomatic. The great majority of endometrial polyps are benign, but malignancy occurs in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, diagnosis, and management of endometrial polyps are reviewed here. General principles of the evaluation of uterine bleeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348442\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps are localized hyperplastic overgrowths of endometrial glands and stroma around a vascular core that form a sessile or pedunculated projection from the surface of the endometrium (",
"    <a class=\"graphic graphic_picture graphicRef70855 \" href=\"UTD.htm?16/28/16839\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Smooth muscle is sometimes present.",
"   </p>",
"   <p>",
"    Single or multiple polyps may occur and range in diameter from a few millimeters to several centimeters (",
"    <a class=\"graphic graphic_picture graphicRef51898 \" href=\"UTD.htm?41/55/42870\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/5\">",
"     5",
"    </a>",
"    ]. Polyps can develop anywhere in the uterine cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348450\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several molecular mechanisms have been proposed to play a role in the development of endometrial polyps. These include monoclonal endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/6\">",
"     6",
"    </a>",
"    ], overexpression of endometrial aromatase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Like uterine leiomyomas, polyps have characteristic cytogenetic rearrangements. Rearrangements in the high-mobility group (HMG) family of transcription factors appear to play a pathogenic role [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometrial polyps express both estrogen and progesterone receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/13\">",
"     13",
"    </a>",
"    ]. In polyps, as in normal endometrial tissue, progesterone may serve an antiproliferative function. This has been demonstrated in a subset of women with polyps, ie, those on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/14\">",
"     14",
"    </a>",
"    ]. While androgens have been found to cause endometrial atrophy, similar to progestins, data suggest that testosterone does not substitute for progestational activity for polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348583\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps are rare among adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/16\">",
"     16",
"    </a>",
"    ]. The frequency of polyps is difficult to establish, since there are few data and some polyps are asymptomatic. Among clinically recognized polyps, the prevalence appears to rise steadily with increasing age, and to be higher in premenopausal than postmenopausal women (6 versus 12 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/17\">",
"     17",
"    </a>",
"    ]. Among women undergoing endometrial biopsy or hysterectomy, the prevalence of endometrial polyps is 10 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350511\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps express both estrogen and progesterone receptors, although studies differ on whether these appear to have pathogenic importance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. Most risk factors for endometrial polyps involve increased levels or activity of endogenous or exogenous estrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348852\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyps develop in 2 to 36 percent of postmenopausal women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Polyps in these women may be large (&gt;2 cm), multiple, or show molecular alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/11,21,23,24\">",
"     11,21,23,24",
"    </a>",
"    ]. Data from a large randomized trial of breast cancer chemoprophylaxis in postmenopausal women found that the incidence of polyps was higher in women treated with tamoxifen compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    (2.1 versus 0.6 percent; relative risk 0.30, 95% CI 0.25-0.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of the levonorgestrel-releasing intrauterine device (IUD) may decrease the incidence of endometrial polyps in women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . This was supported by one small randomized trial that found a statistically significant decrease in the rate of polyps at 12-month follow-up with use of the IUD compared with no treatment (2 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/14\">",
"     14",
"    </a>",
"    ]. Further study is needed. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350380\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps appear to be associated with obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. As an example, in a retrospective cohort study of 223 women planning to undergo in vitro fertilization, those with a BMI &ge;30 had a significantly higher rate of polyps than other women (52 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/26\">",
"     26",
"    </a>",
"    ]; however, these data may not be generalizable to other women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348860\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that postmenopausal hormone therapy is associated with endometrial polyps, particularly regimens with a high dose of estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a progestin with low antiestrogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/25,28\">",
"     25,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with Lynch syndrome may have an increased incidence of endometrial polyps compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349326\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps are typically identified in association with abnormal uterine bleeding. Many polyps are asymptomatic and are discovered as the result of an evaluation for infertility, a finding of endometrial cells on cervical cytology, or as an incidental finding on endometrial sampling, pelvic imaging, or hysteroscopy. In some women, prolapse of the polyp occurs and it can be visualized at the external cervical os during pelvic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348945\">",
"    <span class=\"h2\">",
"     Abnormal uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding, which is usually described by the patient as vaginal bleeding, is the most common presenting symptom and occurs in 64 to 88 percent of women with polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/17,30\">",
"     17,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metrorrhagia is the most frequent symptom in premenopausal women with endometrial polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/31\">",
"     31",
"    </a>",
"    ]. The volume of bleeding is usually small, and may be just spotting. Some women experience heavier bleeding between menstrual cycles or menorrhagia. Postmenopausal bleeding is another common presentation; some postmenopausal women with polyps have breakthrough bleeding during hormonal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link&amp;anchor=H3#H3\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with abnormal uterine bleeding may require evaluation for endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H281205#H281205\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Abnormal uterine bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16476748\">",
"    <span class=\"h2\">",
"     Incidental finding on imaging or hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial polyps are often identified incidentally on a pelvic ultrasound performed for other indications. In addition, some polyps are discovered at time of hysteroscopy, if this study is performed without a prior ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348987\">",
"    <span class=\"h2\">",
"     Endometrial cells on cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology is not a useful method for diagnosing endometrial polyps. Studies have shown an association between the finding of benign endometrial cells on liquid cervical cytology testing and both benign and malignant endometrial neoplasms. In a large retrospective chart review of women age 40 years or older with a cervical cytology report that included the presence of endometrial cells and underwent endometrial sampling, 12 percent of women had endometrial polyps alone and 2 percent had polyps with a coexistent diagnosis (ie, hyperplasia or endometritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/32\">",
"     32",
"    </a>",
"    ]. Among the women with polyps alone, 72 percent were asymptomatic. The evaluation of endometrial cells on cervical cytology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link&amp;anchor=H17#H17\">",
"     \"Cervical cytology: Interpretation of results\", section on 'Benign-appearing endometrial cells in a woman &ge;40 years'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351444\">",
"    <span class=\"h2\">",
"     Prolapsed polyp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, an endometrial polyp prolapses and is visible at the time of speculum examination at the external cervical os. Prolapsed polyps may be symptomatic or asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16476692\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a suspected endometrial polyp are typically evaluated with pelvic imaging or hysteroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349427\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal ultrasound (TVUS) is the first line imaging study of choice of evaluation of women with abnormal uterine bleeding. This modality is effective at characterizing uterine and adnexal lesions and is less expensive than other modalities.",
"   </p>",
"   <p>",
"    For women with an uncertain finding on ultrasound alone or who are candidates for expectant management, we suggest sonohysterography, also referred to as saline infusion sonogram (SIS) or diagnostic hysteroscopy. A systematic review of over 5000 women reported a similar performance for the diagnosis of polyps for all three modalities: sensitivity (TVUS: 91 percent; SIS: 95 percent; hysteroscopy: 90 percent) and specificity (90 and 92 and 93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/17\">",
"     17",
"    </a>",
"    ]. Both SIS and hysteroscopy give a better sense of the shape of the lesion than TVUS alone. The advantage of SIS compared with hysteroscopy is that the adnexa are also visualized, so this modality is useful in women with suspected adnexal pathology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70574 \" href=\"UTD.htm?29/29/30162\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74624 \" href=\"UTD.htm?17/45/18130\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54170 \" href=\"UTD.htm?0/28/450\">",
"     image 3",
"    </a>",
"    ). On the other hand, diagnostic hysteroscopy allows direct visualization of the lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hysteroscopy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16476706\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a prolapsed polyp, there are no physical examination findings associated with an endometrial polyp. A prolapsed polyp can be visualized during a speculum examination, typically as a globular, friable, pedunculated lesion protruding from the external cervical os.",
"   </p>",
"   <p>",
"    A polypoid lesion at the external cervical os is most commonly a cervical polyp, but may be a prolapsed endometrial polyp or leiomyoma. In general, a cervical polyp is identified by visualizing or palpating a stalk originating from the endocervical canal, while the stalk of an endometrial polyp originates from the uterine cavity. Prolapsed leiomyomas typically have a firm consistency, while polyps are soft and friable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Polyps'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link&amp;anchor=H735961#H735961\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\", section on 'Incidental finding on pelvic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an endometrial polyp is a histologic diagnosis based upon the evaluation of the specimen after it has been removed. Histologic evaluation can also exclude malignancy.",
"   </p>",
"   <p>",
"    The specimen is usually collected at time of polypectomy. In some women, an endometrial polyp is diagnosed on an office endometrial biopsy performed to evaluate abnormal uterine bleeding. In such cases, polypectomy should still be performed if indicated (for symptom relief or to exclude malignancy), since the entire polyp may not have been removed with the endometrial biopsy. (See",
"    <a class=\"local\" href=\"#H10071598\">",
"     'Polypectomy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351461\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an endometrial polyp includes other structural lesions of the uterine cavity, primarily intracavitary leiomyomas. It is usually, but not always, possible to differentiate between these lesions with sonography. In addition, polyps and fibroids typically have different appearances when visualized with hysteroscopy. Polyps often have a beefy red appearance, and are usually thinner and less likely to be sessile. In addition, they are soft and friable when touched with an instrument. In contrast, myomas are firm and are mainly white in color with small surface blood vessels. The final determination is made with histology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An endometrial lesion on ultrasound may also represent endometrial hyperplasia or cancer. At hysteroscopy, polyps are generally well-demarcated, in contrast with endometrial neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H281548#H281548\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Pelvic sonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of a prolapsed endometrial polyp includes a cervical polyp and a prolapsed leiomyoma. The approach to differentiating between these lesions is discussed above. (See",
"    <a class=\"local\" href=\"#H16476706\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Continued growth or regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study on the course of endometrial polyps performed two saline infusion sonograms 2.5 years apart on 64 initially asymptomatic women (mean age 44 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/33\">",
"     33",
"    </a>",
"    ]. Seven women had polyps on the first examination. Four of these women had spontaneous regression of their polyps at the second scan, while seven women developed new polyps over the 2.5-year interval. Polyps larger than 1 cm were least likely to regress. Hormone use did not appear to affect the natural history of the polyps, but the study sample was small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 95 percent of endometrial polyps are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/34\">",
"     34",
"    </a>",
"    ]. A systematic review of 17 observational studies including over 10,000 women reported that the incidence of polyps that were malignant or hyperplastic was significantly higher in postmenopausal compared with premenopausal women (5.4 versus 1.7 percent; RR 3.86; 95% CI 2.9&ndash;5.1) and those with bleeding compared to those without bleeding (4.2 versus 2.2 percent; RR 2.0; 95% CI 1.2&ndash;3.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/2\">",
"     2",
"    </a>",
"    ]. Of note, these characteristics are also associated with an increased risk of endometrial malignancy without polyps.",
"   </p>",
"   <p>",
"    The systematic review found that data were inconsistent regarding whether increased polyp size was associated with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/34\">",
"     34",
"    </a>",
"    ]. Studies of 400 or more women that support this association have reported that premalignant or malignant histology was associated with polyps greater than 1.5 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant transformation of an endometrial polyp appears to occur more frequently in women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (up to 11 percent) than in other women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/21\">",
"     21",
"    </a>",
"    ]. There is no evidence for an association between malignancy and polyp size or duration of tamoxifen therapy. Likewise, tamoxifen use is associated with an increase in the overall risk of endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H843977#H843977\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of women with malignant endometrial polyps is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link&amp;anchor=H20#H20\">",
"     \"Endometrial carcinoma: Histopathology and pathogenesis\", section on 'Carcinoma involving an endometrial polyp'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349191\">",
"    <span class=\"h2\">",
"     Effect on fertility and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women undergoing evaluation for infertility may have a finding of an endometrial polyp on ultrasound or hysteroscopy; the reported prevalence in those undergoing in vitro fertilization is 6 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. There are few data regarding the impact of removal on fertility. A systematic review based upon limited data concluded that removing polyps was beneficial in infertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/1\">",
"     1",
"    </a>",
"    ]; this conclusion was based primarily on a single randomized trial (n = 204) that showed a higher pregnancy rate in women undergoing intrauterine insemination who underwent polyp removal compared with hysteroscopy alone (63 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10072410\">",
"     'Symptomatic women'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Endometrial polyps do not appear to be associated with an increased risk of spontaneous abortion or adverse obstetric outcomes. In studies performed in women with a recent miscarriage, the prevalence of polyps was the same as in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H348583\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1500838\">",
"    <span class=\"h1\">",
"     CHOOSING A MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic endometrial polyps should be removed in all women. The goal of polypectomy is both relief of symptoms and detection of malignancy, since symptomatic polyps are more likely to be malignant. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk of malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Management of asymptomatic polyps depends upon the likelihood of malignancy associated with a polyp and whether removal is indicated due to infertility. There are no data from randomized trials to guide therapy of asymptomatic polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10071246\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072410\">",
"    <span class=\"h3\">",
"     Symptomatic women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic polyps should be removed, regardless of menopausal status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072417\">",
"    <span class=\"h3\">",
"     Asymptomatic women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women, we suggest removal of asymptomatic polyps for women with risk factors for endometrial hyperplasia or cancer (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For other asymptomatic women, we perform polypectomy if the following characteristics are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyp &gt;1.5 cm in diameter",
"     </li>",
"     <li>",
"      Multiple polyps",
"     </li>",
"     <li>",
"      Polyp prolapsed through the cervix",
"     </li>",
"     <li>",
"      Infertility (see",
"      <a class=\"local\" href=\"#H1501259\">",
"       'Infertile women'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some studies report that polyps &gt;1.5 cm in diameter are associated with an increased risk of malignancy or hyperplasia, although the data are inconsistent regarding polyp size (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk of malignancy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Multiple polyps and prolapsed polyps are unlikely to regress and are likely to become symptomatic, in our clinical experience. In addition, prolapsed polyps are typically removed easily in an outpatient setting.",
"   </p>",
"   <p>",
"    If symptoms develop, polypectomy should be performed.",
"   </p>",
"   <p>",
"    For women managed expectantly, there are studies regarding the need for continued surveillance. In our practice, we don&rsquo;t perform further surveillance in these patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501259\">",
"    <span class=\"h4\">",
"     Infertile women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data regarding the impact of removal of an endometrial polyp on fertility are limited, as discussed above. Current evidence is insufficient to make a recommendation, although most clinicians perform polypectomy in infertile women. (See",
"    <a class=\"local\" href=\"#H349191\">",
"     'Effect on fertility and pregnancy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10071254\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women, we recommend removal of all endometrial polyps. The risk of malignancy in a polyp is highest in postmenopausal women and the risk of complications associated with polypectomy is low. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk of malignancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10071598\">",
"     'Polypectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501288\">",
"    <span class=\"h2\">",
"     Women with recurrent polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, endometrial polyps recur after removal. In such cases, care should be taken to completely remove the polyp(s) in a repeat polypectomy procedure. There are no data regarding management of recurrent endometrial polyps. One option is a levonorgestrel-releasing intrauterine device, given its reported efficacy in women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/14\">",
"     14",
"    </a>",
"    ]. Endometrial ablation is also an option for women who have completed their childbearing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10071598\">",
"    <span class=\"h1\">",
"     POLYPECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polypectomy under hysteroscopic guidance is the treatment of choice for most endometrial polyps.",
"   </p>",
"   <p>",
"    Hysteroscopic visualization of the polyp is the preferred approach, since blind curettage may miss small polyps and other structural abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Hysteroscopic instruments that may be used to remove a polyp include: grasping forceps, microscissors, electrosurgical loop (ie, resectoscope), morcellator, or a bipolar electrosurgical probe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/42,45,46\">",
"     42,45,46",
"    </a>",
"    ]. Some surgeons visualize the polyp via hysteroscopy and then remove it using a blind approach (eg, using Randall polyp forceps or a Kelly clamp) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/47\">",
"     47",
"    </a>",
"    ]. If this approach is used, the hysteroscope should be used again after polypectomy to confirm complete removal of the polyp.",
"   </p>",
"   <p>",
"    For women with symptomatic polyps, polypectomy results in improvement of symptoms in 75 to 100 percent of patients, based upon studies with follow-up intervals of 2 to 52 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7336/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of hysteroscopic polypectomy are infrequent, and the risk is the same as for other hysteroscopic procedures. General principles of hysteroscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of hysteroscopy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, an endometrial polyp prolapses through the cervix and can be removed vaginally. A polypoid lesion at the external cervical os is most commonly a cervical polyp, but may be a prolapsed endometrial polyp or leiomyoma (see",
"    <a class=\"local\" href=\"#H16476706\">",
"     'Physical examination'",
"    </a>",
"    above). The procedure for removal of a prolapsed endometrial polyp is the same as for a prolapsed leiomyoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link&amp;anchor=H5351763#H5351763\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\", section on 'Vaginal myomectomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Women who undergo removal of a prolapsed polyp without dilation of the cervix and visualization of complete removal should be counseled about the potential for recurrence. The risk of recurrence in this situation is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial polyps are hyperplastic overgrowths of endometrial glands and stroma that form a projection from the surface of the endometrium (lining of the uterus). (See",
"      <a class=\"local\" href=\"#H348442\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among women undergoing endometrial biopsy or hysterectomy, the prevalence of endometrial polyps is 10 to 24 percent. (See",
"      <a class=\"local\" href=\"#H348583\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial polyps are a common cause of abnormal uterine bleeding in both premenopausal and postmenopausal women. They may also be asymptomatic. (See",
"      <a class=\"local\" href=\"#H349326\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The great majority of endometrial polyps are benign, but malignancy occurs in some women. Endometrial polyps are more likely to be malignant in women who are postmenopausal and those who present with bleeding. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transvaginal ultrasound alone is typically sufficient for women who have an indication for surgical management with operative hysteroscopy. For women with an uncertain finding on ultrasound alone or who are candidates for expectant management, we suggest sonohysterography (saline infusion sonogram) or diagnostic hysteroscopy. (See",
"      <a class=\"local\" href=\"#H349427\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an endometrial polyp is a histologic diagnosis based upon the evaluation of the specimen after it has been removed. Histologic evaluation can also exclude malignancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For premenopausal women, symptomatic polyps require removal. We also suggest removal of asymptomatic polyps in premenopausal women with risk factors for endometrial hyperplasia or cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Polypectomy is also a reasonable option for women with polyps that are &gt;1.5 cm, multiple, or prolapsed, or for women who are infertile. (See",
"      <a class=\"local\" href=\"#H1500838\">",
"       'Choosing a management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women, we recommend removal of all endometrial polyps (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1500838\">",
"       'Choosing a management approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/1\">",
"      Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand 2010; 89:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/2\">",
"      Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:1197.",
"     </a>",
"    </li>",
"    <li>",
"     Mutter GL, Nucci, MR, Robboy SJ. Endometritis, metaplasias, polyps, and miscellaneous changes. In: Robboy's Pathology of the Female Reproductie Tract, 2nd ed., Robboy SJ, Mutter GL, Prat J, et al.  (Eds), Churchill Livingston Elsevier, Oxford 2009. p.343.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/4\">",
"      Kim KR, Peng R, Ro JY, Robboy SJ. A diagnostically useful histopathologic feature of endometrial polyp: the long axis of endometrial glands arranged parallel to surface epithelium. Am J Surg Pathol 2004; 28:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/5\">",
"      Gregoriou O, Konidaris S, Vrachnis N, et al. Clinical parameters linked with malignancy in endometrial polyps. Climacteric 2009; 12:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/6\">",
"      Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/7\">",
"      Maia H Jr, Pimentel K, Silva TM, et al. Aromatase and cyclooxygenase-2 expression in endometrial polyps during the menstrual cycle. Gynecol Endocrinol 2006; 22:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/8\">",
"      Pal L, Niklaus AL, Kim M, et al. Heterogeneity in endometrial expression of aromatase in polyp-bearing uteri. Hum Reprod 2008; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/9\">",
"      Dal Cin P, Vanni R, Marras S, et al. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res 1995; 55:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/10\">",
"      Nogueira AA, Sant'Ana de Almeida EC, Poli Neto OB, et al. Immunohistochemical expression of p63 in endometrial polyps: evidence that a basal cell immunophenotype is maintained. Menopause 2006; 13:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/11\">",
"      Dal Cin P, Timmerman D, Van den Berghe I, et al. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 1998; 58:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/12\">",
"      Tallini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 2000; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/13\">",
"      Gul A, Ugur M, Iskender C, et al. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and its relationship to clinical parameters. Arch Gynecol Obstet 2010; 281:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/14\">",
"      Chan SS, Tam WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007; 114:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/15\">",
"      Filho AM, Barbosa IC, Maia H Jr, et al. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women. Gynecol Endocrinol 2007; 23:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/16\">",
"      Davis VJ, Dizon CD, Minuk CF. Rare cause of vaginal bleeding in early puberty. J Pediatr Adolesc Gynecol 2005; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/17\">",
"      Salim S, Won H, Nesbitt-Hawes E, et al. Diagnosis and management of endometrial polyps: a critical review of the literature. J Minim Invasive Gynecol 2011; 18:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/18\">",
"      Van Bogaert LJ. Clinicopathologic findings in endometrial polyps. Obstet Gynecol 1988; 71:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/19\">",
"      Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 2001; 80:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/20\">",
"      Kuokkanen S, Pal L. Steroid hormone receptor profile of premenopausal endometrial polyps. Reprod Sci 2010; 17:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/21\">",
"      Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/22\">",
"      Runowicz CD, Costantino JP, Wickerham DL, et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol 2011; 205:535.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/23\">",
"      Althuis MD, Sexton M, Langenberg P, et al. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 2000; 89:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/24\">",
"      McGurgan P, Taylor LJ, Duffy SR, O'Donovan PJ. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen. Maturitas 2006; 54:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/25\">",
"      Oguz S, Sargin A, Kelekci S, et al. The role of hormone replacement therapy in endometrial polyp formation. Maturitas 2005; 50:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/26\">",
"      Onalan R, Onalan G, Tonguc E, et al. Body mass index is an independent risk factor for the development of endometrial polyps in patients undergoing in vitro fertilization. Fertil Steril 2009; 91:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/27\">",
"      Reslov&aacute; T, Tosner J, Resl M, et al. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet 1999; 262:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/28\">",
"      Maia H Jr, Maltez A, Studard E, et al. Effect of previous hormone replacement therapy on endometrial polyps during menopause. Gynecol Endocrinol 2004; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/29\">",
"      L&eacute;curu F, Metzger U, Scarabin C, et al. Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. Fam Cancer 2007; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/30\">",
"      Golan A, Sagiv R, Berar M, et al. Bipolar electrical energy in physiologic solution--a revolution in operative hysteroscopy. J Am Assoc Gynecol Laparosc 2001; 8:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/31\">",
"      Hassa H, Tekin B, Senses T, et al. Are the site, diameter, and number of endometrial polyps related with symptomatology? Am J Obstet Gynecol 2006; 194:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/32\">",
"      Beal HN, Stone J, Beckmann MJ, McAsey ME. Endometrial cells identified in cervical cytology in women &gt; or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196:568.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/33\">",
"      DeWaay DJ, Syrop CH, Nygaard IE, et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/34\">",
"      Baiocchi G, Manci N, Pazzaglia M, et al. Malignancy in endometrial polyps: a 12-year experience. Am J Obstet Gynecol 2009; 201:462.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/35\">",
"      Ferrazzi E, Zupi E, Leone FP, et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol 2009; 200:235.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/36\">",
"      Ben-Arie A, Goldchmit C, Laviv Y, et al. The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004; 115:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/37\">",
"      Fatemi HM, Kasius JC, Timmermans A, et al. Prevalence of unsuspected uterine cavity abnormalities diagnosed by office hysteroscopy prior to in vitro fertilization. Hum Reprod 2010; 25:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/38\">",
"      Karayalcin R, Ozcan S, Moraloglu O, et al. Results of 2500 office-based diagnostic hysteroscopies before IVF. Reprod Biomed Online 2010; 20:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/39\">",
"      P&eacute;rez-Medina T, Bajo-Arenas J, Salazar F, et al. Endometrial polyps and their implication in the pregnancy rates of patients undergoing intrauterine insemination: a prospective, randomized study. Hum Reprod 2005; 20:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/40\">",
"      Cogendez E, Dolgun ZN, Sanverdi I, et al. Post-abortion hysteroscopy: a method for early diagnosis of congenital and acquired intrauterine causes of abortions. Eur J Obstet Gynecol Reprod Biol 2011; 156:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/41\">",
"      Souza CA, Schmitz C, Genro VK, et al. Office hysteroscopy study in consecutive miscarriage patients. Rev Assoc Med Bras 2011; 57:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/42\">",
"      Preutthipan S, Herabutya Y. Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women. Fertil Steril 2005; 83:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/43\">",
"      Brooks PG, Serden SP. Hysteroscopic findings after unsuccessful dilatation and curettage for abnormal uterine bleeding. Am J Obstet Gynecol 1988; 158:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/44\">",
"      Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol 1988; 158:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/45\">",
"      Muzii L, Bellati F, Pernice M, et al. Resectoscopic versus bipolar electrode excision of endometrial polyps: a randomized study. Fertil Steril 2007; 87:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/46\">",
"      Emanuel MH, Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005; 12:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/47\">",
"      Gebauer G, Hafner A, Siebzehnr&uuml;bl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 2001; 184:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7336/abstract/48\">",
"      Nathani F, Clark TJ. Uterine polypectomy in the management of abnormal uterine bleeding: A systematic review. J Minim Invasive Gynecol 2006; 13:260.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5457 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7336=[""].join("\n");
var outline_f7_10_7336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348442\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348450\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348583\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350511\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348852\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350380\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348860\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349326\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348945\">",
"      Abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16476748\">",
"      Incidental finding on imaging or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348987\">",
"      Endometrial cells on cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351444\">",
"      Prolapsed polyp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16476692\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349427\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16476706\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351461\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Continued growth or regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349191\">",
"      Effect on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1500838\">",
"      CHOOSING A MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10071246\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072410\">",
"      - Symptomatic women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072417\">",
"      - Asymptomatic women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1501259\">",
"      Infertile women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10071254\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1501288\">",
"      Women with recurrent polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10071598\">",
"      POLYPECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5457|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/29/30162\" title=\"diagnostic image 1\">",
"      Endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/45/18130\" title=\"diagnostic image 2\">",
"      Large endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/28/450\" title=\"diagnostic image 3\">",
"      Sonogram endometrial polyp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5457|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/28/16839\" title=\"picture 1\">",
"      Endometrial polyp histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/55/42870\" title=\"picture 2\">",
"      Endometrial polyps at hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 1\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=related_link\">",
"      Endometrial carcinoma: Histopathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7337="Overview of hypertension in acute and chronic kidney disease";
var content_f7_10_7337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"71\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hypertension in acute and chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7337/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7337/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7337/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7337/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7337/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/10/7337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17855060\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a frequent finding in both acute and chronic kidney disease, particularly with glomerular or vascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathogenesis and preferred treatment of hypertension vary with the type of renal disease and its duration. This topic will summarize the pathogenesis and treatment of hypertension in patients with acute and chronic kidney disease and then direct the reader, when necessary, to more detailed discussions in other topics. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF HYPERTENSION IN KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hypertension varies with the type of disease (eg, glomerular versus vascular) and with the duration of disease (acute versus chronic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Acute glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute glomerular disease, such as poststreptococcal glomerulonephritis, tend to be volume expanded and edematous due to sodium retention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the elevation in blood pressure is primarily due to fluid overload, as evidenced by suppression of the renin-angiotensin-aldosterone system and enhanced release of atrial natriuretic peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these changes are most prominent with severe disease, the incidence of hypertension is increased even in patients with a normal serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/4\">",
"     4",
"    </a>",
"    ]. Both a familial predisposition to hypertension and subclinical volume expansion are thought to be important in this setting.",
"   </p>",
"   <p>",
"    Experimental studies of the nephrotic syndrome or glomerulonephritis suggest that sodium retention in these disorders is due to increased reabsorption in the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/5\">",
"     5",
"    </a>",
"    ]. Two different abnormalities in collecting tubule function have been identified in glomerular disease, both of which could increase sodium reabsorption:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relative resistance to atrial natriuretic peptide, due at least in part to more rapid degradation of the second messenger cyclic GMP (guanosine monophosphate) by the enzyme phosphodiesterase [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/4\">",
"       4",
"      </a>",
"      ]. In an animal model of nephrotic syndrome, infusion of a phosphodiesterase inhibitor largely reverses this defect and restores the normal natriuretic response to volume expansion.",
"     </li>",
"     <li>",
"      Increased activity of the Na-K-ATPase pump in the cortical collecting tubule but not other nephron segments [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/6\">",
"       6",
"      </a>",
"      ]. This pump provides the energy for active sodium transport by pumping reabsorbed sodium out the cell into the peritubular capillary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How these changes might be induced by the nephrotic syndrome or glomerulonephritis is not clear. They are not likely to be mediated by aldosterone, the secretion of which is reduced by volume expansion-mediated reductions in plasma renin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is also common in acute vascular diseases, such as vasculitis or scleroderma renal crisis. In these settings, the elevation in blood pressure results from ischemia-induced activation of the renin-angiotensin system rather than volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/2\">",
"     2",
"    </a>",
"    ]. This difference in mechanism between glomerular and vascular disease may be of therapeutic importance. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Treatment of hypertension in acute glomerular or vascular disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is present in approximately 80 to 85 percent of patients with chronic kidney disease (CKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence of hypertension is elevated in patients with kidney damage and a normal glomerular filtration rate, and increases further as the glomerular filtration rate falls. &nbsp;Data from the Modification of Diet in Renal Disease Study, for example, showed that the prevalence of hypertension rose progressively from 65 to 95 percent as the glomerular filtration rate fell from 85 to 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/8\">",
"     8",
"    </a>",
"    ]. As in patients without renal disease, the prevalence of hypertension is also higher in patients with higher body weight and in blacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link&amp;anchor=H2#H2\">",
"     \"Obesity and weight reduction in hypertension\", section on 'Pathogenesis of hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=see_link\">",
"     \"Hypertensive complications in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of factors can contribute to the increased prevalence of hypertension in patients with CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium retention is generally of primary importance, even though the degree of extracellular volume expansion may be insufficient to induce edema.",
"     </li>",
"     <li>",
"      Increased activity of the renin-angiotensin system is often responsible for at least part of the hypertension that persists after the restoration of normovolemia, particularly in patients with vascular disease since renal ischemia is a potent stimulus of renin secretion. Regional ischemia induced by scarring may also play a role.",
"     </li>",
"     <li>",
"      Hypertension can be a causative (eg, hypertensive nephrosclerosis) or contributory factor in the development of kidney disease.",
"     </li>",
"     <li>",
"      Hypertension may result from enhanced activity of the sympathetic nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/9\">",
"       9",
"      </a>",
"      ]. The afferent signal may arise in part within the failing kidneys, since it is not seen in patients who have undergone bilateral nephrectomy.",
"     </li>",
"     <li>",
"      Secondary hyperparathyroidism raises the intracellular calcium concentration, which can lead to vasoconstriction and hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/10\">",
"       10",
"      </a>",
"      ]. Lowering parathyroid hormone secretion by the chronic administration of an active vitamin D analog can reduce both intracellular calcium and the systemic blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis of renal osteodystrophy\", section on 'Secondary hyperparathyroidism and osteitis fibrosa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with erythropoietin may increase blood pressure, an effect that is in part related to the degree of elevation in the hematocrit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link&amp;anchor=H2#H2\">",
"       \"Hypertension following erythropoietin in chronic kidney disease\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Impaired nitric oxide synthesis and endothelium-mediated vasodilatation has been demonstrated in patients with uremia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/11\">",
"       11",
"      </a>",
"      ]. Although the mechanisms are unclear, potential explanations include reduced nitric oxide availability due to a state of increased oxidative stress, or cofactor deficiency-induced uncoupling of nitric oxide synthase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the factors that can raise the mean arterial pressure, two other factors may be important:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage renal disease are more likely to have an increase in central pulse pressure and isolated systolic hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/12\">",
"       12",
"      </a>",
"      ]. Why this occurs is incompletely understood but increased aortic stiffness probably plays an important role.",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease may not demonstrate the normal nocturnal decline in blood pressure (such patients are called \"nondippers\"), a possible risk factor for hypertensive complications [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"       \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF HYPERTENSION IN ACUTE GLOMERULAR OR VASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the differences in pathogenesis, the mechanism and treatment of hypertension varies in patients with acute glomerular and vascular disease.",
"   </p>",
"   <p>",
"    We prefer initial therapy with diuretics (particularly loop diuretics in patients with reduced glomerular filtration rates) to treat hypertension in patients with acute glomerular disease and edema, since diuretics will also treat the hypervolemia and associated edema. If the hypertension persists, angiotensin converting enzyme (ACE) inhibitors may be effective, even in the low renin hypertension often associated with acute glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/14\">",
"     14",
"    </a>",
"    ]. This response may reflect activation of tissue renin-angiotensin systems, such as that in the kidney, vascular endothelium, and adrenal gland. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison with acute glomerulonephritis, we prefer ACE inhibitors as initial antihypertensive therapy in patients with acute vascular diseases, since renal ischemia leads to activation of the renin-angiotensin system. Strong data support this approach in patients with scleroderma renal crisis and we prefer angiotensin inhibition in polyarteritis nodosa and other vasculitides as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H18#H18\">",
"     \"Scleroderma renal crisis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"     \"Treatment and prognosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT OF HYPERTENSION IN CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of even mild hypertension is important in patients with chronic kidney disease (CKD) to protect against both progressive renal function loss and cardiovascular disease, the incidence of which is increased with mild to moderate CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2011 KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease that goal blood pressure depends upon the degree of proteinuria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with proteinuric CKD, usually defined as greater than or equal to 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or higher, the blood pressure should be lowered to less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      In patients with nonproteinuric CKD, defined as less than 500",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the blood pressure should be lowered to less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence supporting our recommendations for goal blood pressure in patients with diabetic and nondiabetic CKD is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blood pressure goal is somewhat different in elderly patients with isolated systolic hypertension. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to blood pressure control, specific goals related to a reduction in urinary protein excretion have been formulated to slow the rate of progression of proteinuric CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a proteinuria goal of less than 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      In patients who are initially nephrotic and in whom this goal is unobtainable, we attempt to achieve a minimum reduction in proteinuria of at least 50 to 60 percent from baseline values",
"      <strong>",
"       plus",
"      </strong>",
"      protein excretion less than 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence supporting our recommendations for proteinuria reduction in patients with diabetic and nondiabetic CKD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H35#H35\">",
"     \"Treatment of diabetic nephropathy\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H685755\">",
"    <span class=\"h3\">",
"     Technique of blood pressure measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly every trial that evaluated blood pressure goals or specific antihypertensive therapies in patients with CKD employed office-based, as opposed to ambulatory or home, blood pressure measurements. In addition, ambulatory blood pressure monitoring is cumbersome and expensive. Thus, we use office-based measurements to determine whether or not patients have achieved goal blood pressure. The appropriate technique for measuring blood pressure in the office is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, several observational studies have found that 24-hour ambulatory blood pressure is a stronger predictor of end-stage renal disease (ESRD), cardiovascular disease, and death than office-based measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In 436 patients with CKD who underwent both ambulatory and office-based blood pressure measurements, for example, a daytime ambulatory systolic pressure greater than 145 mmHg was associated with a threefold increased risk of developing cardiovascular disease and a nearly twofold increased risk of ESRD or death compared with patients whose daytime systolic pressure was 126 to 135 mmHg. The prognostic value of nighttime ambulatory blood pressure was even stronger. In contrast, the mean of six office-based measurements taken over two days was not associated with cardiovascular disease, ESRD, or death.",
"   </p>",
"   <p>",
"    Ambulatory blood pressure monitoring and home blood pressure monitoring, which is less expensive than ambulatory blood pressure monitoring, are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17855216\">",
"    <span class=\"h2\">",
"     Benefits of sodium restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium restriction enhances the effect of many antihypertensive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link&amp;anchor=H12#H12\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Response to antihypertensive drugs'",
"    </a>",
"    .) This is also true in patients with CKD most of whom, as discussed below, are treated with angiotensin inhibitors to slow disease progression. The potential benefits of sodium restriction were demonstrated in a crossover trial of 52 patients with proteinuric CKD (mean protein excretion of 1.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and mean creatinine clearance of 70",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    all of whom were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/17\">",
"     17",
"    </a>",
"    ]. Four treatments were given in random order, each for six weeks: a low sodium diet with placebo; a low sodium diet with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    ; a regular sodium diet with placebo; and a regular sodium diet with valsartan. Compared with a regular sodium diet (mean urinary sodium excretion 184",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    a low sodium diet (mean 106",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    decreased blood pressure to a greater degree than addition of valsartan (11 versus 3 mmHg). Addition of valsartan had a minimal additional effect (2 mmHg) on blood pressure beyond a low sodium diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140207190\">",
"    <span class=\"h2\">",
"     Use of diuretics and goal of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the reduction in renal function, higher doses of diuretics are typically required in patients with CKD who are usually volume expanded even in the absence of edema. Thiazide diuretics become less effective when the glomerular filtration rate is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/18\">",
"     18",
"    </a>",
"    ]. In such patients, loop diuretics are preferred as initial therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"     Torsemide",
"    </a>",
"    , which has a long duration of action, may be preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of resistant hypertension\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If edema persists, a thiazide diuretic can be added to the loop diuretic. The rationale for combined therapy is that most of the fluid leaving the loop of Henle, even after the administration of a loop diuretic, is reabsorbed in the distal tubule, the site of action of thiazide diuretics. Thus, thiazides have an enhanced diuretic effect in patients treated with a loop diuretic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of refractory edema in adults\", section on 'Thiazide plus loop diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of combined diuretic therapy has been illustrated in a report of five patients with CKD (serum creatinine 2.3 to 4.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [203 to 433",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    who had an inadequate response to 160 to 240",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    in divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/19\">",
"     19",
"    </a>",
"    ]. Increasing the furosemide dose had only limited efficacy. In contrast, the addition of 25 to 50 mg twice daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    produced a marked diuresis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    is generally preferred to hydrochlorothiazide because it is more potent and has a longer duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of resistant hypertension\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In edematous patients with CKD, the initial goal is removal of edema. However, if hypertension persists once edema has been removed, plasma volume expansion may still be present and contribute to the hypertension. Thus, when diuretics are used to treat hypertension in patients with CKD without overt edema, the dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency of diuretic should be increased when the antihypertensive response is inadequate.",
"   </p>",
"   <p>",
"    Diuretic therapy should be increased until one of two end points is reached: the blood pressure goal is achieved; or the patient has attained \"dry weight\" which, in the presence of persistent hypertension, is defined as the weight at which further fluid loss leads to symptoms (cramps, fatigue, orthostatic hypotension) or to decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the serum creatinine concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attainment of goal blood pressure in patients with CKD typically requires multidrug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/21\">",
"     21",
"    </a>",
"    ]. As with goal blood pressure discussed above, the choice of agent depends in part upon whether or not the patients have proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2001790\">",
"    <span class=\"h3\">",
"     Sequence of antihypertensive therapy in proteinuric CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CKD who have proteinuria, defined as a protein excretion greater than or equal to 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    we recommend angiotensin inhibitors as first-line therapy. We suggest diuretics and non-dihydropyridine calcium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) as second-line and third-line agents, although loop diuretics would be a first-line therapy with angiotensin inhibitors in patients with edema. When using angiotensin inhibitors and diuretics in combination as first-line therapy, we titrate the dose of the second drug slowly to avoid hypotension since diuretics enhance the antihypertensive effect of angiotensin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link&amp;anchor=H5#H5\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\", section on 'Antihypertensive response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2001983\">",
"    <span class=\"h4\">",
"     First-line therapy in proteinuric CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality evidence favors the use of an ACE inhibitor or angiotensin II receptor blocker (ARB) as first-line therapy in patients with proteinuric CKD (ie, protein excretion greater than 500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    because, in addition to lowering the blood pressure, these drugs slow the rate of progression of CKD. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Choice of antihypertensive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common side effects of angiotensin inhibition in patients with CKD include an acute reduction in glomerular filtration rate and hyperkalemia. In addition, both ACE inhibitors and ARBs are contraindicated in pregnancy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of ACE inhibitors or ARBs to manage hypertension in children with CKD is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2002011\">",
"    <span class=\"h4\">",
"     Second- and third-line therapy in proteinuric CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggestions for second- and third-line antihypertensive therapy in patients with proteinuric CKD depend upon whether overt volume overload is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with CKD who have proteinuria and",
"      <strong>",
"       edema",
"      </strong>",
"      , initial therapy usually consists of both an angiotensin inhibitor for renal protection and a loop diuretic for edema, which, by increasing renin release, may also enhance the antihypertensive effect of the angiotensin inhibitor. The use of a diuretic may also restore the antiproteinuric effect of ACE inhibitor therapy in patients without an adequate antiproteinuric response, since volume expansion reduces angiotensin II release and makes the blood pressure less dependent upon angiotensin II [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link&amp;anchor=H5#H5\">",
"       \"Renin-angiotensin system inhibition in the treatment of hypertension\", section on 'Antihypertensive response'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If further antihypertensive therapy is required, we suggest a non-dihydropyridine calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) since these drugs also lower proteinuria. In contrast, dihydropyridines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) have little or no effect on protein excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H79963019#H79963019\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Calcium channel blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with CKD who have proteinuria but",
"      <strong>",
"       not edema",
"      </strong>",
"      , we suggest either a diuretic or a non-dihydropyridine calcium channel blocker as second-line and then third-line therapy. Volume expansion, even in the absence of edema, often plays a major role in hypertension associated with CKD. (See",
"      <a class=\"local\" href=\"#H140207190\">",
"       'Use of diuretics and goal of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to diuretic use and the goal and limitations of diuretic therapy are discussed above. (See",
"    <a class=\"local\" href=\"#H140207190\">",
"     'Use of diuretics and goal of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2001798\">",
"    <span class=\"h3\">",
"     Sequence of antihypertensive therapy in nonproteinuric CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to their renoprotective effects in proteinuric CKD, angiotensin inhibitors do",
"    <strong>",
"     not",
"    </strong>",
"    appear to be more beneficial than other antihypertensive agents in patients with nonproteinuric CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/25\">",
"     25",
"    </a>",
"    ]. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H594171#H594171\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Lack of benefit in nonproteinuric CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with nonproteinuric CKD, we suggest the following sequence, which depends upon the presence or absence of edema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients",
"      <strong>",
"       with edema",
"      </strong>",
"      , we prefer initial therapy with a loop diuretic. Once the edema is controlled, an angiotensin inhibitor or a dihydropyridine calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) can be added in either order if hypertension persists.",
"     </li>",
"     <li>",
"      In patients",
"      <strong>",
"       without edema",
"      </strong>",
"      , we start with an angiotensin inhibitor, and then add a dihydropyridine calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) as second-line therapy. This approach has not been studied specifically in patients with nonproteinuric CKD. Rather, it is extrapolated from our recommendations for hypertensive patients in general, which are guided by the findings of the ACCOMPLISH trial. If needed, we suggest adding a diuretic as third-line therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H9#H9\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACCOMPLISH trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3036563\">",
"    <span class=\"h3\">",
"     Fourth-line therapy with other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antihypertensive drugs can be used as necessary in patients with CKD who have resistant hypertension. An aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) is an effective fourth-line agent for the treatment of resistant hypertension in general and in patients with CKD. In addition to reducing blood pressure, aldosterone antagonists also have antiproteinuric properties that may be associated with a slower decline in renal function. However, trials with patient-important outcomes are not available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of aldosterone antagonists was evaluated in a study of 46 patients with a mean estimated glomerular filtration rate (eGFR) of 57",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 and hypertension that was not controlled with three mechanistically complementary drugs, including a diuretic and angiotensin inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/26\">",
"     26",
"    </a>",
"    ]. The mean fall in systolic pressure induced by aldosterone antagonists was 14.7 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of resistant hypertension\", section on 'Aldosterone antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main adverse effects of aldosterone antagonists in patients with CKD are a reduction in kidney function and hyperkalemia. In the above study, 39 percent had a decline in estimated glomerular filtration rate (eGFR) of 30 percent or more when goal blood pressure was achieved and 17 percent developed hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/26\">",
"     26",
"    </a>",
"    ]. Risk factors for hyperkalemia included a baseline eGFR &le;45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in patients with a serum potassium above 4.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and a fall in eGFR of more than 30 percent after therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3128354\">",
"    <span class=\"h2\">",
"     Possible benefit from nocturnal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average nocturnal blood pressure is approximately 15 percent lower than daytime values. Failure of the blood pressure to fall by at least 10 percent during sleep is called \"nondipping\", and is one of the strongest predictors of adverse cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with CKD are nondippers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/16\">",
"     16",
"    </a>",
"    ]. Shifting one antihypertensive medication from the morning to the evening can restore the normal nocturnal blood pressure dip in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of shifting at least one antihypertensive medication from the morning to the evening on the incidence of cardiovascular disease was evaluated in an open-label randomized trial of 661 patients with chronic kidney disease (defined as an estimated glomerular filtration rate below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 or an albumin-to-creatinine ratio greater than 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    on two separate occasions) who were randomly assigned to take all medications in the morning or to take at least one at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/28\">",
"     28",
"    </a>",
"    ]. At baseline, the two groups had similar mean ambulatory blood pressure",
"    <span class=\"nowrap\">",
"     (135/77",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     135/79",
"    </span>",
"    mmHg) and proportion of nondippers (68 versus 65 percent). The only medication classes permitted to be taken at bedtime were ACE inhibitors, ARBs, or long-acting calcium channel blockers.",
"   </p>",
"   <p>",
"    The following findings were noted through 5.4 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean ambulatory blood pressure remained similar between the groups, and there was no change in nocturnal blood pressure or the proportion of nondippers in patients who continued to take all antihypertensive drugs in the morning. In contrast, patients assigned to take at least one medication at bedtime had significant reductions in both nocturnal blood pressure (from",
"      <span class=\"nowrap\">",
"       129/73",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       117/65",
"      </span>",
"      mmHg) and the proportion of nondippers (from 65 to 41 percent).",
"     </li>",
"     <li>",
"      Taking at least one medication at bedtime resulted in significantly fewer major vascular events, defined as myocardial infarction, stroke, or cardiovascular death (2.7 versus 7.8 percent). Most of the benefit was driven by a significant reduction in the incidence of myocardial infarction (1.5 versus 4.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar observations have been made in hypertensive patients without CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H2528233#H2528233\">",
"     \"Overview of hypertension in adults\", section on 'Possible benefit from nocturnal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious concerns about this trial include its open label design and small number of events. In addition, the effect size (a 72 percent reduction in the relative risk of myocardial infarction, stroke, or cardiovascular death) is considerably larger than the true effects of most rigorously studied interventions. As an example, treating hypertensive patients with antihypertensive medications reduces the relative risk of cardiovascular events by 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/29\">",
"     29",
"    </a>",
"    ]. However, there seems to be little downside to taking at least one (non-diuretic) antihypertensive medication at night while awaiting additional data to confirm the clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Maintenance dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major therapeutic goal in hypertensive dialysis patients is gradual fluid removal to attain \"dry weight\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9190086\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute glomerular disease tend to be volume expanded and edematous due to sodium retention. As a result, the elevation in blood pressure is thought to be primarily due to fluid overload, as evidenced by suppression of the renin-angiotensin-aldosterone system and enhanced release of atrial natriuretic peptide. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute glomerular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute vascular diseases, such as vasculitis or scleroderma, the elevation in blood pressure results from ischemia-induced activation of the renin-angiotensin system rather than volume expansion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic kidney disease (CKD), hypertension is likely due to a combination of factors including sodium retention, increased activity of the renin-angiotensin system, and enhanced activity of the sympathetic nervous system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hypertension in acute glomerular disease with edema typically resolves after fluid removal with diuretics or, if necessary, dialysis. In comparison, lowering angiotensin II formation with an angiotensin converting enzyme (ACE) inhibitor is effective in many patients with vasculitis or scleroderma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of hypertension in acute glomerular or vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CKD, the goal blood pressure depends upon the degree of proteinuria. The evidence for this approach is presented and evaluated in separate topics (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with proteinuric CKD, we recommend a blood pressure goal of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg rather than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H257963561#H257963561\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of goal blood pressure on progression of CKD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with nonproteinuric CKD, we recommend a blood pressure goal of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with",
"      <strong>",
"       proteinuric",
"      </strong>",
"      (defined as protein excretion above 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      CKD, we recommend an ACE inhibitor or angiotensin receptor blocker as first-line therapy for the treatment of hypertension (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of diabetic nephropathy\", section on 'Preservation of renal function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with proteinuric CKD who also have edema, initial therapy usually consists of both an angiotensin inhibitor for renal protection and a loop diuretic for edema which, by increasing renin release, may also enhance the antihypertensive effect of the angiotensin inhibitor. In such patients who require additional antihypertensive therapy, we suggest a non-dihydropyridine calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) since these drugs also lower proteinuria (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2002011\">",
"       'Second- and third-line therapy in proteinuric CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with proteinuric CKD who do not have edema, we suggest using a diuretic or a non-dihydropyridine calcium channel blocker as second-line, with the other as third-line therapy if needed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2002011\">",
"       'Second- and third-line therapy in proteinuric CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to their renoprotective effects in proteinuric CKD, angiotensin inhibitors do",
"      <strong>",
"       not",
"      </strong>",
"      appear to be more beneficial than other antihypertensive agents in patients with",
"      <strong>",
"       nonproteinuric",
"      </strong>",
"      CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7337/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H594171#H594171\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Lack of benefit in nonproteinuric CKD'",
"      </a>",
"      .) We therefore use the following approach in patients with nonproteinuric CKD (see",
"      <a class=\"local\" href=\"#H2001798\">",
"       'Sequence of antihypertensive therapy in nonproteinuric CKD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with nonproteinuric CKD who have edema, we suggest initiation of a diuretic as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Once the edema is controlled, an ACE inhibitor or angiotensin receptor blocker or dihydropyridine calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) can be added in either order if hypertension persists.",
"     </li>",
"     <li>",
"      In patients with nonproteinuric CKD who do not have edema, we suggest an ACE inhibitor or angiotensin receptor blocker as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If needed, a dihydropyridine calcium channel blocker and diuretic can be added as second and third line therapy, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other antihypertensive drugs can be used as necessary in patients with CKD who have treatment resistant hypertension. An aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) is an effective fourth-line agent for the treatment of resistant hypertension in general and in patients with CKD, although these drugs increase the risk for hyperkalemia. (See",
"      <a class=\"local\" href=\"#H3036563\">",
"       'Fourth-line therapy with other agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CKD who require antihypertensive therapy, we suggest that at least one medication (but not a diuretic) be taken at bedtime rather than taking all medications in the morning (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3128354\">",
"       'Possible benefit from nocturnal therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/1\">",
"      Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int 2009; 75:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/2\">",
"      Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/3\">",
"      Rodr&iacute;guez-Iturbe B, Colic D, Parra G, Gutkowska J. Atrial natriuretic factor in the acute nephritic and nephrotic syndromes. Kidney Int 1990; 38:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/4\">",
"      Valentin JP, Qiu C, Muldowney WP, et al. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992; 90:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/5\">",
"      Buerkert J, Martin DR, Trigg D, Simon EE. Sodium handling by deep nephrons and the terminal collecting duct in glomerulonephritis. Kidney Int 1991; 39:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/6\">",
"      Zolty E, Ibnou-Zekri N, Izui S, et al. Glomerulonephritis and sodium retention: enhancement of Na+/K+-ATPase activity in the collecting duct is shared by rats with puromycin induced nephrotic syndrome and mice with spontaneous lupus-like glomerulonephritis. Nephrol Dial Transplant 1999; 14:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/7\">",
"      Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/8\">",
"      Buckalew VM Jr, Berg RL, Wang SR, et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996; 28:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/9\">",
"      Neumann J, Ligtenberg G, Klein II, et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/10\">",
"      Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/11\">",
"      Passauer J, Pistrosch F, B&uuml;ssemaker E, et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 2005; 16:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/12\">",
"      London G, Guerin A, Pannier B, et al. Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension 1992; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/13\">",
"      Portaluppi F, Montanari L, Massari M, et al. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens 1991; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/14\">",
"      Parra G, Rodr&iacute;guez-Iturbe B, Colina-Chourio J, Garc&iacute;a R. Short-term treatment with captopril in hypertension due to acute glomerulonephritis. Clin Nephrol 1988; 29:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/15\">",
"      Minutolo R, Agarwal R, Borrelli S, et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011; 171:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/16\">",
"      Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/17\">",
"      Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/18\">",
"      REUBI FC, COTTIER PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 1961; 23:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/19\">",
"      Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/20\">",
"      Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/21\">",
"      Khosla, N, Kalaitzidis, R, Bakris, GL. The kidney, hypertension, and remaining challenges. Med Clin N Am 2009; 93: 697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/22\">",
"      Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/23\">",
"      Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003; 14:3217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/24\">",
"      Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/25\">",
"      Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/26\">",
"      Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/27\">",
"      Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/28\">",
"      Hermida RC, Ayala DE, Moj&oacute;n A, Fern&aacute;ndez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7337/abstract/29\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3872 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7337=[""].join("\n");
var outline_f7_10_7337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9190086\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17855060\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PATHOGENESIS OF HYPERTENSION IN KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Acute glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF HYPERTENSION IN ACUTE GLOMERULAR OR VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT OF HYPERTENSION IN CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H685755\">",
"      - Technique of blood pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17855216\">",
"      Benefits of sodium restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H140207190\">",
"      Use of diuretics and goal of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2001790\">",
"      - Sequence of antihypertensive therapy in proteinuric CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2001983\">",
"      First-line therapy in proteinuric CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2002011\">",
"      Second- and third-line therapy in proteinuric CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2001798\">",
"      - Sequence of antihypertensive therapy in nonproteinuric CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3036563\">",
"      - Fourth-line therapy with other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3128354\">",
"      Possible benefit from nocturnal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9190086\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7338="Treatment of relapsed or refractory follicular lymphoma";
var content_f7_10_7338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory follicular lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/10/7338/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/10/7338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of patients treated for FL will have an initial response to therapy with 40 to 80 percent demonstrating a complete response, depending upon the initial regimen used. Unfortunately, conventional therapy for FL is not curative and virtually all of these patients will ultimately develop progressive disease. In addition, less than 10 percent of patients treated with initial chemoimmunotherapy will not respond to treatment (ie, refractory disease).",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory FL is discussed here. The treatment of previously untreated FL is presented separately as are the epidemiology, clinical presentation, pathologic features, diagnosis, and pathobiology of follicular lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION OF SUSPECTED RELAPSE OR RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial therapy, patients are followed at routine intervals to monitor for treatment-related complications and relapse. At these visits, patients are evaluated with a history, physical examination, and blood work. Imaging studies are reserved for the evaluation of suspected relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Long-term management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677725#H19677725\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Long-term management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive disease (PD) or relapse after complete remission (CR) most commonly presents as asymptomatic enlargement of the lymph nodes, liver, or spleen. By definition, PD or relapse after CR reflects the appearance of any new lesion, a 50 percent increase in the longest diameter of a previously identified lesion, or",
"    <span class=\"nowrap\">",
"     new/recurrent",
"    </span>",
"    involvement of the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 1",
"    </a>",
"    ). Not all patients with PD or relapsed disease require imaging studies or biopsy at the time of progression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging studies (eg, computed tomography) are typically postponed until repeat treatment is indicted in order to provide a new baseline of disease activity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Lymph node biopsy should be performed if histologic transformation is suspected. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Histologic transformation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A bone marrow biopsy is indicated if cytopenias are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Refractory (resistant) disease is defined as occurring in those patients who fail to obtain an at least partial response with initial treatment as determined by an at least 50 percent decrease in lesion size with no new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An integral part of the natural history of FL is progression to a higher grade histologic subtype, such as diffuse large B-cell lymphoma. Signs or symptoms that suggest histologic transformation include the rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites (excluding the bone marrow), development of systemic symptoms (eg, fever, weight loss, night sweats), elevated serum lactate dehydrogenase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalcemia.",
"   </p>",
"   <p>",
"    Lymph node biopsy should be performed if histologic transformation is suspected. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asymptomatic recurrent FL do not necessarily require immediate treatment, but should be followed closely for the development of symptomatic disease. In general, the same indications for treatment used for first-line therapy are used at the time of relapse or progressive disease. These are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675522#H19675522\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic FL or those with an increase in disease tempo require treatment. There is no standard therapy for patients with relapsed or refractory FL and practice varies widely; as such, patients should be encouraged to participate in clinical trials whenever possible. Often, a \"risk stratified\" approach is used such that patients who appear to have more aggressive disease are treated with more intensive therapies at the time of relapse.",
"   </p>",
"   <p>",
"    The main treatment options for patients with relapsed or refractory FL include (",
"    <a class=\"graphic graphic_table graphicRef77636 \" href=\"UTD.htm?12/1/12316\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical trials of new agents or new combinations of existing agents",
"     </li>",
"     <li>",
"      Immunotherapy either with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or rituximab plus chemotherapy",
"     </li>",
"     <li>",
"      Radioimmunotherapy with radiolabeled antibodies",
"     </li>",
"     <li>",
"      Rechallenge of original therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      High dose chemotherapy with autologous hematopoietic cell transplantation (HCT) rescue",
"     </li>",
"     <li>",
"      Allogeneic HCT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these options must take into account both tumor and patient characteristics that may have impact on efficacy and how the treatment may affect future therapies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunotherapy either with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      alone or rituximab plus chemotherapy is a treatment option for most patients with relapsed or refractory disease. Single agent rituximab has response rates as high as 40 percent with minimal toxicity. When other chemotherapy agents are added, response rates increase, as do toxicities. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunotherapy based treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radioimmunotherapy (RIT) has demonstrated response rates of approximately 60 to 80 percent. However, RIT is not recommended for patients with poor bone marrow reserve or high tumor burden in the bone marrow and requires coordination with physicians trained in the safe use of radionucleotides. Early evidence suggests that patients relapsing following treatment with RIT may tolerate other treatment approaches including chemotherapy, external beam radiation therapy, and autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Radioimmunotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      High dose chemotherapy with autologous HCT rescue can prolong the progression-free and overall survival rates of patients in complete response or with minimal disease at the time of HCT. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Transplantation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Allogeneic HCT may be curative in a highly selected cohort of patients. Eligibility is primarily determined based upon the patient's age, performance status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of comorbid conditions. Otherwise fit patients with a poor response to initial therapy, or short remission duration may be ideal candidates for this approach in first or second remission. However, HCT may affect bone marrow reserve and the ability to perform RIT in the future or vice versa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link\">",
"       \"Hematopoietic cell transplantation in follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy is primarily used for the palliation of patients who have symptoms related to a single disease site. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients with relapsed or refractory FL, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , either alone or in combination with chemotherapy, rather than chemotherapy alone or RIT. Patients with a poor performance status may prefer single agent rituximab for its relatively low toxicity profile, while patients with a good performance status may prefer combination therapy for its superior response rates despite greater toxicity and no proven improvement in survival rates. RIT is an excellent treatment alternative for eligible patients, but is not as commonly employed due to the complexity of administration.",
"   </p>",
"   <p>",
"    The choice of treatment at relapse should also take into account the patient's response to initial therapy. Patients who have an initial response duration significantly less than the mean progression-free survival (PFS) for an individual treatment regimen may be considered for more aggressive treatment at relapse, such as the use of autologous HCT. PFS differs greatly by treatment regimen. Patients who receive extended dose single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as first line therapy for FL have a median PFS of approximately two years, while patients who receive initial treatment with rituximab plus combination chemotherapy demonstrate median PFS of three to seven years, depending upon the regimen used. As an example, a relapse within two years of initial treatment with R-CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus rituximab) chemotherapy, which has a median PFS of greater than four years, would be considered significantly shorter than the mean. Such patients should be considered for aggressive therapy (eg, HCT) at the time of relapse. In contrast, a patient relapsing four years after treatment with single agent rituximab would be an ideal candidate for retreatment with single agent rituximab.",
"   </p>",
"   <p>",
"    These various treatment modalities are discussed in more detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMMUNOTHERAPY BASED TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies (ie, immunotherapy) are a key component to the treatment of patients with FL; as discussed separately, their incorporation into initial therapy results in superior response rates, progression free survival, and overall survival when compared with chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675536#H19675536\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Immunotherapy-based treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is also used, either alone or in combination with chemotherapy, in the treatment of relapsed or refractory FL, including patients who demonstrated an objective clinical response to an initial course of rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/5\">",
"     5",
"    </a>",
"    ]. The major toxicities of rituximab include infusion reactions (ie, fevers, rigors, and hypotension) and infections related to immunosuppression. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several prospective randomized trials and one meta-analysis have examined the role of interferon as immunotherapy in advanced stage disease patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/6-16\">",
"     6-16",
"    </a>",
"    ]. Given the variability of results of the various trials, the expense and toxicity of treatment, as well as the lack of trials in which interferon was employed along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and other newer treatment regimens, use of interferon following intensive chemotherapy does not appear to be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of FL demonstrated responses in approximately half of previously treated patients. Rituximab has since been incorporated into the initial treatment of most patients with FL.",
"   </p>",
"   <p>",
"    A phase II trial studied the safety and efficacy of retreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in 57 patients with relapsed, advanced, indolent NHL (92 percent FL), all of whom had previously responded to rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall response rate was 40 percent, with 11 percent complete remissions; estimated median time to progression after treatment was 18 months. Side effects were mild to moderate (grades 1 or 2) and self-limited, and resembled those seen on initial treatment. No patient developed a human antichimeric antibody (HACA) response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is used in combination with many different chemotherapy regimens for the treatment of relapsed or refractory FL. This approach is supported by numerous studies including a large meta-analysis that demonstrated superior response rates and overall survival when rituximab was added to conventional chemotherapy in patients with previously treated or previously untreated FL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/18\">",
"     18",
"    </a>",
"    ]. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675536#H19675536\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Immunotherapy-based treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal chemotherapy regimen to administer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is unknown. While numerous chemotherapy regimens have demonstrated activity in relapsed or refractory FL, none has been compared directly in a randomized trial. In addition, response rates reported in clinical trials cannot be accurately compared due to changes over time in the response assessment and response definitions. As such, a choice among chemotherapy regimens in this setting is primarily made based upon the patient&rsquo;s exposure to prior chemotherapy, the regimens&rsquo; expected toxicities, and the clinician&rsquo;s experience with the regimen.",
"   </p>",
"   <p>",
"    The following are examples of regimens that have demonstrated activity in the relapsed or refractory setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      <strong>",
"       , and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      <strong>",
"       (R-CVP)",
"      </strong>",
"      &mdash; R-CVP is commonly used for the treatment of newly diagnosed FL. Side effects are generally mild with gastrointestinal toxicities and peripheral neuropathy most common [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia occurs in approximately 25 percent. In previously untreated FL, responses are seen in approximately 80 percent (40 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      <strong>",
"       (BR)",
"      </strong>",
"      &mdash; BR is another regimen used for the initial treatment of FL. Two phase II trials of BR in a total of 130 patients with relapsed or refractory NHL (49 percent FL) reported response rates of 90 to 92 percent (55 to 60 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Median progression-free survival was approximately two years. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity was myelosuppression with leukopenia (16 to 36 percent) and thrombocytopenia (3 to 9 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      <strong>",
"       , and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      <strong>",
"       (R-CHOP)",
"      </strong>",
"      &mdash; R-CHOP has been compared with CHOP alone in the treatment of relapsed or refractory FL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effect is granulocytopenia (63 percent). Other common side effects are generally mild to moderate alopecia, nausea, vomiting, and infusion related reactions. There is a 1 percent treatment related mortality rate. Overall response rate was 85 percent. Median time to progression was 33 months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <strong>",
"       , plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      <strong>",
"       (FCR)",
"      </strong>",
"      &mdash; Two phase II trials evaluated the use of FCR in patients with FL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Overall responses were seen in 87 percent of previously treated patients with complete remissions seen in 67 to 74 percent. Median time to disease progression was not reached after a median follow-up of 45 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/30\">",
"       30",
"      </a>",
"      ]. The most common toxicities were transient and hematologic. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia, anemia, and thrombocytopenia were seen in 40, 4, and 6 percent of patients, respectively. Other common, mild or moderate toxicities include opportunistic infections (eg, herpes) and infusion reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"       \"Overview of infectious complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <strong>",
"       , and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      <strong>",
"       (R-FCM)",
"      </strong>",
"      &mdash; A randomized trial that included 147 patients with relapsed or refractory NHL (44 percent FL) randomly assigned treatment with four monthly cycles of FCM with or without rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients assigned to R-FCM had superior overall (79 versus 58 percent) and complete (34 versus 12 percent) response rates compared with those assigned to FCM. Accrual to this randomization was discontinued after 147 patients because of the superiority of R-FCM; 134 subsequent patients received R-FCM for induction, with overall and complete response rates of 86 and 25 percent, respectively.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; The combination of bortezomib plus rituximab has reported overall response rates of 45 to 60 percent in FL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. A phase III randomized trial compared bortezomib plus rituximab to rituximab alone in 676 patients with relapsed or refractory FL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/36\">",
"       36",
"      </a>",
"      ]. Bortezomib plus rituximab resulted in higher rates of overall (63 versus 49 percent) and complete response (25 versus 18 percent). While there was a statistically significant increase in median progression-free survival of approximately two months (11 versus 13 months), the clinical benefit of such an improvement was unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/37\">",
"       37",
"      </a>",
"      ]. The combination of bortezomib plus rituximab was associated with increased toxicity (eg, gastrointestinal distress, neuropathy, infections). Given the lack of meaningful benefit, we do not advocate the use of this combination.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      <strong>",
"       ,",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      <strong>",
"       , and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; Two multicenter phase II trials have investigated the use of bendamustine, bortezomib, and rituximab in patients with relapsed or refractory indolent NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Common toxicities include nausea (50 percent), neuropathy (47 percent), fatigue (47 percent), constipation (40 percent), and fever (40 percent). One patient died of sepsis. A response is seen in approximately 90 percent of patients with a complete response in approximately 50 percent of patients. The median duration of response is approximately 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/39\">",
"       39",
"      </a>",
"      ]. Given the relatively indolent clinical nature of FL, the high rate of neuropathy with this regimen limits its widespread use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with relapsed or refractory FL undergoing chemoimmunotherapy, we suggest R-CVP, R-CHOP, or BR (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ). This preference is based largely upon our clinical experience with these regimens. A choice between these regimens can be made based upon the patient&rsquo;s history of prior therapy (eg, R-CHOP or R-CVP for patient who had received BR). As examples, R-CHOP or R-CVP may be preferred for a patient who has previously received BR, while BR may be preferred for a patient who has previously received R-CVP or R-CHOP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RADIOIMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioimmunotherapy (RIT) refers to the use of monoclonal antibodies that are linked to radioisotopes (eg, yttrium-90 or iodine-131). There are several anti-CD20 radioimmunoconjugates that have been developed for the treatment of FL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. Two of these have been approved by the United States FDA for the treatment of patients with relapsed or refractory FL, including patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -refractory FL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       Ibritumomab",
"      </a>",
"      tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody conjugated to Yttrium-90.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       Tositumomab",
"      </a>",
"      (Bexxar) is a murine anti-CD20 monoclonal antibody conjugated with radioactive Iodine-131.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     Ibritumomab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    have not been directly compared in a prospective, randomized trial. Prospective trials of these agents demonstrate response rates of 60 to 80 percent in previously treated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/46-54\">",
"     46-54",
"    </a>",
"    ]. Median progression-free survival is less than one year, but patients who achieve a complete response have a median time to progression of close to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       Ibritumomab",
"      </a>",
"      (0.3",
"      <span class=\"nowrap\">",
"       mCi/kg;",
"      </span>",
"      11",
"      <span class=\"nowrap\">",
"       MBq/kg)",
"      </span>",
"      was administered to 30 patients with relapsed or refractory low-grade NHL who had received a median of two prior treatments (range: one to nine) and were mildly thrombocytopenic (platelet counts 100,000 to",
"      <span class=\"nowrap\">",
"       150,000/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/47\">",
"       47",
"      </a>",
"      ]. Overall response rate was 83 percent, with 37 percent complete remissions. Toxicity was transient and reversible; the incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33, 13, and 3 percent, respectively (",
"      <a class=\"graphic graphic_table graphicRef64984 \" href=\"UTD.htm?25/21/25948\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a study of 60 patients with previously-treated (median of 4 prior chemotherapy regimens) relapsed or resistant low-grade or transformed low-grade NHL, a single dose of Bexxar resulted in an overall response rate of 65 percent (20 percent CR) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/57\">",
"       57",
"      </a>",
"      ]. The median duration of remission had not been reached by 47 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older adults (ie, &ge;70 years) demonstrate similar rates of response, response duration, and have a similar safety profile when compared with younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial demonstrated superior response rates with RIT when compared with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . This prospective trial of 143 patients with relapsed or refractory NHL (79 percent FL) randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    or rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients assigned to ibritumomab demonstrated significantly higher overall (80 versus 56 percent) and complete (30 versus 16 percent) response rates. Median duration of response (14.2 versus 12.1 months) and time to progression (11.2 versus 10.2 months) were not significantly different.",
"   </p>",
"   <p>",
"    Private and academic clinicians have been slow to adopt RIT in the treatment of FL, perhaps related to the complicated administration. It is unknown how RIT compares with chemoimmunotherapy, whether it should be combined with chemotherapy, or whether it is safe to give repeat doses upon relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial reported on a regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and autologous stem cell transplantation in patients with relapsed B-cell NHL (73 percent FL) with an estimated two-year overall survival rate of 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thirty-two patients with relapsed disease after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      reported overall and complete response rates following retreatment of 56 and 25 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/61\">",
"       61",
"      </a>",
"      ]. Median duration of the second remission for all patients was 15 months, and was 35 months for the 8 patients with a complete response. Toxicity was appreciable, and was similar to that experienced with initial treatment. Only 62 percent of patients were able to receive full doses and 6 of the 32 patients (19 percent) developed a second malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    are similar except that tositumomab is associated with hypothyroidism in 10 to 20 percent of patients while a link between ibritumomab and hypothyroidism has not been reported.",
"   </p>",
"   <p>",
"    Both of these agents can be associated with an infusion reaction similar to that seen with other monoclonal antibodies. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H28#H28\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Other anti-CD20 monoclonal antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most profound side effects of RIT are potentially prolonged and significant cytopenias with cell count nadirs ranging from four to nine weeks post-therapy with recovery one to four weeks post-nadir. The most common cytopenias are leucopenia and thrombocytopenia, which are easily managed in the majority of patients. Both agents also cause a transient depletion of B cells for about six to nine months, but have not been associated with significant increases in severe infections or hospitalizations.",
"   </p>",
"   <p>",
"    Although initial reports suggested a possible risk of treatment-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (t-AML), the rate of t-MDS and t-AML does not appear to be increased. The overall incidence of",
"    <span class=\"nowrap\">",
"     t-MDS/t-AML",
"    </span>",
"    in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    was initially reported at 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/62\">",
"     62",
"    </a>",
"    ]. A lower incidence (3.5 percent) has since been reported in a survey of 995 patients with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    indolent lymphoma treated with this agent and in none of the 76 patients receiving this agent as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/63\">",
"     63",
"    </a>",
"    ]. An evaluation of 746 patients treated for NHL with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    found that the rates of t-MDS and t-AML were not increased compared with historic rates in those who had received multiple chemotherapeutic regimes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    differ in their details, some general concepts apply to both of these agents.",
"   </p>",
"   <p>",
"    A bilateral bone marrow biopsy is required prior to the initiation of RIT to assess bone marrow involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/65\">",
"     65",
"    </a>",
"    ]. RIT is not recommended in patients with inadequate marrow reserve (ie, platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL,",
"    </span>",
"    absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;1500/microL,",
"    </span>",
"    bone marrow cellularity &lt;15 percent), lymphoma bone marrow involvement &gt;25 percent, or previous radiation to &gt;25 percent of active marrow sites.",
"   </p>",
"   <p>",
"    Both of these agents can be administered to outpatients. RIT is complicated and should only be administered by those qualified in the safe use of therapeutic doses of radionucleotides. The general timing of therapy is outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A non-radiolabeled antibody (eg, unlabeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      for Bexxar;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      ) is administered approximately one week prior to RIT in order to bind circulating lymphoid cells thereby minimizing binding of these cells by RIT. This minimizes systemic toxicity and maximizes the localization of RIT to disease sites.",
"     </li>",
"     <li>",
"      Next, a \"dosimetric\" dose of RIT is administered. This allows for the calculation of individual body drug clearance in the case of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      and, in conjunction with a whole body scan, checks for the normal biodistribution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      . RIT is not given to patients who demonstrate increased uptake in the lungs, urinary tract, or bowel.",
"     </li>",
"     <li>",
"      Finally, RIT is administered.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       Potassium iodide",
"      </a>",
"      or Lugol's solution must be used for thyroid protection with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Radiation safety measures differ between the two agents.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       Ibritumomab",
"      </a>",
"      is a pure beta emitter with 90 percent of its energy absorbed within a radius of 5.3 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/66\">",
"       66",
"      </a>",
"      ]. As such, physical contact with loved ones after administration is not limited except that sexual intercourse and kissing should be avoided in the first 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/67\">",
"       67",
"      </a>",
"      ]. In comparison,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      is both a gamma and beta emitter and is excreted in the urine. Other persons must remain at a distance of several feet for three to four days and urine must be double flushed down the toilet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the risk of delayed hematologic toxicity, patients should have blood count monitoring at least weekly following treatment until hematologic recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of either autologous or allogeneic hematopoietic cell transplantation (HCT) in FL is controversial and the subject of numerous ongoing clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autologous HCT may prolong progression-free and overall survival rates in a subset of patients who are in complete remission or have minimal disease at the time of HCT.",
"     </li>",
"     <li>",
"      Myeloablative allogeneic HCT has a treatment-related mortality rate that approaches 40 percent, but may be curative in a highly selected cohort of patients. In contrast, reduced-intensity allogeneic HCT appears to have a lower treatment-related mortality (approximately 10 to 20 percent) with an approximately 60 percent long-term progression-free survival rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility for HCT is primarily determined based upon the type of HCT, the patient's age, their performance status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of comorbid conditions. Young, otherwise fit patients with a poor response to initial therapy, or short remission duration should be considered for this approach in first or second remission. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL is extremely responsive to radiation therapy (RT); low dose RT (eg, total dose of 4 Gy) can be used for the palliation of patients who have symptoms related to a single disease site [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In addition, RT is the primary treatment modality used for the initial treatment of stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with FL will not be cured with initial or subsequent therapy. As such, the main goals of therapy are to prolong progression-free survival and minimize therapy-related toxicities. Maintenance therapy with the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    appears to prolong progression-free, and perhaps overall, survival in patients with relapsed FL who did not receive rituximab as part of their initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A two-arm randomized international study of CHOP versus R-CHOP followed by either maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      every three months for a maximum of two years or observation in 465 patients with relapsed or refractory FL found that patients who received maintenance rituximab had significantly longer median progression-free survival (PFS) from the time of second randomization (52 versus 15 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/27\">",
"       27",
"      </a>",
"      ]. A subsequent report of this study, with a median follow-up of six years, confirmed that rituximab maintenance improved median PFS and demonstrated a nonsignificant trend towards improved overall survival rates at five years (74 versus 64 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 202 adults with newly diagnosed or",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      FL who did not progress after four weekly doses of once-weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      were randomly assigned to observation or rituximab infusions at 3, 5, 7, and 9 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/71\">",
"       71",
"      </a>",
"      ]. After a median observation time of 35 months, patients who received extended rituximab dosing had significantly superior median event-free survival (23 versus 12 months). Overall survival rates did not differ.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of the literature and meta-analysis of nine trials including 2586 adult patients with FL reported that patients who received maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    demonstrated the following when compared with patients who were observed or treated with rituximab at the time of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/10/7338/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of severe (grade 3 or 4) toxicities, especially infection-related adverse events (RR = 1.67, 95 percent CI 1.40 to 2.00)",
"     </li>",
"     <li>",
"      Superior rates of overall survival for patients with relapsed disease (HR = 0.72, 95 percent CI = 0.57 to 0.91), but not for patients with previously untreated FL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of patients who have previously received rituximab is unclear. It is reasonable to offer maintenance following the treatment of relapse if the relapse did",
"    <strong>",
"     not",
"    </strong>",
"    occur while the patient was receiving maintenance therapy. This is largely based upon extrapolation of data demonstrating a benefit to the use of maintenance following initial therapy. There is no role for rituximab maintenance in the treatment of patients with FL that is refractory to rituximab (eg, patients who have progressed while receiving rituximab maintenance after initial therapy). In addition, the long-term toxicities associated with rituximab therapy are not yet fully known. There are concerns regarding B-cell depletion, hypogammaglobulinemia, and reactivation of viral infections (eg, hepatitis B). The use of maintenance following initial therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677456#H19677456\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response assessment after the treatment of relapsed FL mirrors that used after initial therapy (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Evaluation of response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are seen at periodic intervals to monitor for treatment complications and assess for progression. Our approach parallels that which we use after initial treatment. This is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677745#H19677745\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"       \"Patient information: Follicular lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of patients treated for follicular lymphoma (FL) will have an initial response to therapy, but virtually all of these patients will ultimately develop progressive disease requiring subsequent treatment.",
"     </li>",
"     <li>",
"      Progressive disease (PD) or relapse after complete remission (CR) most commonly presents as asymptomatic enlargement of the lymph nodes, liver, or spleen. Histologic transformation to a more aggressive variant is suggested by the rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites, development of systemic symptoms, or laboratory abnormalities. Such patients should undergo lymph node biopsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation of suspected relapse or resistance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Histologic transformation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with asymptomatic recurrent FL do not necessarily require immediate treatment, but should be followed closely for the development of symptomatic disease. Patients with symptomatic FL or those with an increase in disease tempo require treatment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standard therapy for patients with relapsed or refractory FL and practice varies widely; as such, patients should be encouraged to participate in clinical trials whenever possible. A choice among potential therapies must take into account characteristics of both the tumor and the patient as well as an evaluation of the initial response to treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with relapsed or refractory FL, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , either alone or in combination with chemotherapy, rather than chemotherapy alone or radioimmunotherapy (RIT) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). RIT is an excellent treatment alternative for eligible patients, but is not as commonly employed due to the complexity of administration. Patients who have an initial response duration significantly less than the mean progression-free survival for an individual treatment regimen may be considered for more aggressive treatment at relapse, such as the use of autologous hematopoietic cell transplantation (HCT). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunotherapy based treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Radioimmunotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A choice between single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and combination chemotherapy plus rituximab depends largely upon the patient&rsquo;s performance status. For patients with a poor performance status, we suggest single agent rituximab for its relatively low toxicity profile (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with a good performance status, we suggest the use of rituximab plus combination chemotherapy for its superior response rates despite greater toxicity and no proven improvement in survival rates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunotherapy based treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with relapsed or refractory FL undergoing chemoimmunotherapy, we suggest R-CVP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ), R-CHOP (cyclophosphamide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , vincristine, and prednisone plus rituximab), or BR (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      plus rituximab) rather than other regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference is based largely upon our clinical experience with these regimens. A choice between these regimens can be made based upon the patient&rsquo;s history of prior therapy. As examples, R-CHOP or R-CVP may be preferred for a patient who has previously received BR, while BR may be preferred for a patient who has previously received R-CVP or R-CHOP. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chemoimmunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autologous or allogeneic HCT may prolong the progression-free and overall survival rates of patients in complete response or with minimal disease at the time of HCT. Eligibility is primarily determined based upon the patient's age, performance status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of comorbid conditions. Young, otherwise fit patients with a poor response to initial therapy or short remission duration may be ideal candidates for this approach in first or second remission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link\">",
"       \"Hematopoietic cell transplantation in follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low dose radiation therapy can be used for the palliation of local disease symptoms. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy with the monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      appears to prolong progression-free, and perhaps overall, survival in patients with relapsed FL who did not receive rituximab as part of their initial therapy. The role of maintenance rituximab in the treatment of patients who have previously received rituximab is unclear. It is reasonable to offer maintenance following the treatment of relapse if the relapse did",
"      <strong>",
"       not",
"      </strong>",
"      occur while the patient was receiving maintenance therapy. There is no role for rituximab maintenance in the treatment of patients with FL that is refractory to rituximab (eg, patients who have progressed while receiving rituximab maintenance after initial therapy). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/1\">",
"      Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/2\">",
"      Justice TE, Martenson JA, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer 2006; 107:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/3\">",
"      Peyrade F, Italiano A, Fontana X, et al. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol 2007; 8:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/4\">",
"      Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 2006; 106:616.",
"     </a>",
"    </li>",
"    <li>",
"     Genentech/Idec Rituxan letter warns of fatal mucocutaneous reactions. The Pink Sheet. F-D-C Reports. volume 63, number 21. May 21, 2001. p.32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/6\">",
"      Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/7\">",
"      Rohatiner A, Radford J, Deakin D, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/8\">",
"      Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/9\">",
"      Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/10\">",
"      Arranz R, Garc&iacute;a-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/11\">",
"      Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/12\">",
"      Solal-C&eacute;ligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/13\">",
"      Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/14\">",
"      Aviles A, Duque G, Talavera A, Guzman R. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996; 20:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/15\">",
"      Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/16\">",
"      Cheson BD. The curious case of the baffling biological. J Clin Oncol 2000; 18:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/17\">",
"      Davis TA, Grillo-L&oacute;pez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/18\">",
"      Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/19\">",
"      Lazzarino M, Arcaini L, Orlandi E, et al. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 2005; 68:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/20\">",
"      Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/21\">",
"      Davis TA, Maloney DG, Grillo-L&oacute;pez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/22\">",
"      Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002; 117:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/23\">",
"      Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/24\">",
"      Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/25\">",
"      Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/26\">",
"      Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/27\">",
"      van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/28\">",
"      van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/29\">",
"      Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/30\">",
"      Sacchi S, Pozzi S, Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007; 110:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/31\">",
"      Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/32\">",
"      Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/33\">",
"      de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27:5023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/34\">",
"      Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/35\">",
"      Coiffier B, Osmanov E, Hong X, et al. A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma (abstract 857). Blood 2010; 116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/36\">",
"      Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011; 12:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/37\">",
"      Salles G. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma? J Clin Oncol 2011; 29:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/38\">",
"      Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/39\">",
"      Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011; 29:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/40\">",
"      Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/41\">",
"      Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest 2003; 21:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/42\">",
"      Forero A, Weiden PL, Vose JM, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004; 104:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/43\">",
"      Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2004; 59:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/44\">",
"      Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006; 107:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/45\">",
"      Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/46\">",
"      Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/47\">",
"      Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/48\">",
"      Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/49\">",
"      Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/50\">",
"      Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/51\">",
"      Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006; 94:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/52\">",
"      Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/53\">",
"      Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:7565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/54\">",
"      Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 2011; 117:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/55\">",
"      Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/56\">",
"      Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/57\">",
"      Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/58\">",
"      Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007; 22:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/59\">",
"      Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/60\">",
"      Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/61\">",
"      Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005; 23:7985.",
"     </a>",
"    </li>",
"    <li>",
"     GSK to balance Bexxar expanded indication against lowered response rates. \"The Pink Sheet\" F-D-C Reports 2005; 67:9. January 10. Information also available on revised drug label.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/63\">",
"      Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/64\">",
"      Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/65\">",
"      Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003; 21:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/66\">",
"      Tennvall J, Fischer M, Bischof Delaloye A, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007; 34:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/67\">",
"      Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/68\">",
"      Ganem G, Cartron G, Girinsky T, et al. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010; 78:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/69\">",
"      Rossier C, Schick U, Miralbell R, et al. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/70\">",
"      Chan EK, Fung S, Gospodarowicz M, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/71\">",
"      Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/10/7338/abstract/72\">",
"      Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103:1799.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4755 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7338=[""].join("\n");
var outline_f7_10_7338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION OF SUSPECTED RELAPSE OR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMMUNOTHERAPY BASED TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RADIOIMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 1\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/1/12316\" title=\"table 2\">",
"      Rx relapsed refractory FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/21/25948\" title=\"table 3\">",
"      Hematologic toxicity grades NCI CTCAE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=related_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_10_7339="ECG manifestations of acute myocardial ischemia";
var content_f7_10_7339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG manifestations of acute myocardial ischaemia (in absence of LVH and LBBB)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ST elevation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New ST elevation at the J-point in two contiguous leads with the cut-off points: &ge;0.2 mV in men or &ge;0.15 mV in women in leads V",
"        <sub>",
"         2",
"        </sub>",
"        -V",
"        <sub>",
"         3",
"        </sub>",
"        and/or &ge;0.1 mV in other leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ST depression and T-wave changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New horizontal or down-sloping ST depression &ge;0.05 mV in two contiguous leads; and/or T inversion &ge;0.1 mVin two contiguous leads with prominent R-wave or R/S ratio &gt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007; 28:2525. Copyright &copy;2007 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7339=[""].join("\n");
var outline_f7_10_7339=null;
var title_f7_10_7340="Schilling test variations";
var content_f7_10_7340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vitamin B12 absorption (Schilling test) in various diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastrectomy, pernicious anemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Celiac disease*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bacterial overgrowth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ileal resection or disease&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pancreatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 + intrinsic factor",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low/normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 + antibiotics",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Low/normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 + gluten-free diet",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Low/normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 + pancreatic enzymes",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The Schilling test may be normal in patients with celiac disease because the terminal ileum is frequently spared. n/a, these stages of the Schilling test are not needed for the disorder.",
"     <br>",
"      &bull; Results depend upon the length of resection or the extent of disease. Values will not normalize with &gt;100 cm of resection. Values may normalize after treatment of active Crohn's disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7340=[""].join("\n");
var outline_f7_10_7340=null;
var title_f7_10_7341="Causes of neonatal seizures";
var content_f7_10_7341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of neonatal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Acute",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acute neonatal encephalopathy (includes classic hypoxic-ischemic encephalopathy, both ante- and intrapartum)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Arterial ischemic stroke",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sinovenous thrombosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Extracorporeal membrane oxygenation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital heart disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vein of Galen malformation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Giant arteriovenous malformation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypertensive encephalopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intracranial hemorrhage (subdural subarachnoid, intraventricular, intraparenchymal)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trauma (intrapartum and nonaccidental)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Infections (sepsis, meningitis, encephalitis)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Transient, simple metabolic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Inborn errors of metabolism (including pyridoxine dependent seizures)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intoxication",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Chronic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isolated cerebral dysgenesis, eg, lissencephaly, hemimegalencephaly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cerebral dysgenesis associated with inborn errors of metabolism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic infection (TORCH [toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex] syndromes)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Neurocutaneous syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Incontinentia pigmenti (Bloch Sulzberger syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypomelanosis of Ito",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Sturge-Weber syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Tuberous sclerosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Linear sebaceous nevus (epidermal nevus syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Genetic conditions",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          22Q11 microdeletion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          ARX (Aristaless-related homeobox) mutations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Specific very early onset epilepsy syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Fifth-day fits (benign neonatal convulsions)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Benign familial neonatal seizures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Early myoclonic encephalopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Early infantile epileptic encephalopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Migrating partial seizures of infancy",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chapman KE, Mizrahi EM, Clancy RR. Neonatal seizures. In: Wyllie's Treatment of Epilepsy: Principles and Practice, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7341=[""].join("\n");
var outline_f7_10_7341=null;
var title_f7_10_7342="Hemodynamic responses during dobutamine infusion";
var content_f7_10_7342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Hemodynamic responses typically seen during dobutamine infusion for cardiac stress testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the changes in blood pressure (BP) and heart rate in beats per min (bpm) during a dobutamine infusion using incremental doses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. J Am Coll Cardiol 1993; 21:1583.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7342=[""].join("\n");
var outline_f7_10_7342=null;
var title_f7_10_7343="Endosc esophageal papilloma";
var content_f7_10_7343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal papilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an esophageal papilloma appearing as an isolated, wart-like exophytic projection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Wild, MD, and Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_10_7343=[""].join("\n");
var outline_f7_10_7343=null;
